annual report roche group annual report group accounts roche holding ltd basel annual accounts key figures millions chf figures reported figures reported financial statements adjusted basisa change change sales ebitdab operating profit net income research development additions property plant equipment personnel number employees december ratios ebitda sales operating profit sales net income sales research development sales data shares nonvoting equity securities chfc earnings per share nonvoting equity security diluted dividend per share nonvoting equity securityd adjusted figures used internal management roche group represent results groups underlying ongoing operations exclude special items include continuing businesses seepages full description reconciliation b ebitda earnings interest financial income tax depreciation amortisation including impairment corresponds operating profit depreciation amortisation including impairment c number shares per share information restated share split took place may see note financial statements dividend proposed board directorsgroup performance glance latot latot latot latot latot sales divisionin millions chf pharmaceuticals diagnostics vitamins fine chemicals fragrances flavours nonvoting equity security genussschein price performance chf roche nonvoting equity security adjusted swiss market index rebased group figures net income millions chf net income per share ebitda millions chf nonvoting equity security chf operating profit millions chf research development millions chf additions property plant equipment millions chf special charges figures adjusted basis figures fully comparable previous years due givaudan spinoff genentech transactions accounting policy changes per share information restated share split took place may roche group annual report group accounts roche holding ltd basel annual accounts table contents letter chairman board directors executive committee divisions pharmaceuticals diagnostics vitamins fine chemicals actionable health information people environment human resources safety environmental protection social involvement finance financial review consolidated financial statements notes consolidated financial statements report group auditors multiyear overview holding finance companies roche securities roche holding ltd basel financial statements notes financial statements appropriation available earnings report statutory auditors roche global market presence operating subsidiaries associated companies table contents every day thousands dedicated roche employees con tribute skills talent innovation companys success excellence healthcaregroup sales local currencies swiss francs increase operating profit margin net income declines slightly result reduced financial income higher tax expenses strong cash flow solid balance sheet pharmaceuticals division profitability improved pharmaceuticals pipeline new molecular entities global leadership diagnostics reinforced diagnostics divisions margins strategic options vitamins fine chemicals division review outlook good results adjusted basisletter chairman overall successful year roche despite numerous challenges reflected particularly markedly improved operating results reported core pharmaceuticals diagnostics businesses year also announced intention acquire majority interest japans chugai pharmaceutical alliance make us leading player worlds secondlargest pharmaceuticals market negative side past anti competitive practices vitamins industry repercussions comparable basis consolidated sales rose year local currencies swiss francs billion swiss francs two particularly letter chairmanpositive highlights increase adjusted operating profit billion swiss francs improvement groups operating profit margin reached result expected decline financial income higher tax expenses adjusted net income fell billion swiss francs roche recorded strong positive cash flow remains solidly financed including many special items recorded reported net income declined previous year billion swiss francs process renewal result number special way three divisions equipped itemsparticularly onetime gain well future growthwe billion swiss francs sale evaluating strategic alternatives genentech shares vitamins fine chemicals nonrecurring restructuring costs division outside roche focus additional provisions recorded sharply core pharmaceu theconsolidated financial state ticals diagnostics businesses ments show yearonyear decline reported net income good overall performance billion swiss francs would possible without great dedication pro roche reported strong positive fessionalism employees displayed challenging yearand cash flow remains solidly financed would like take additional opportunity express apprecia tion contribu improve transparency tion comparability groups current future performanceresults annual general meeting presented actual basis shareholders board directors adjusted basis excludes propose dividend effects special items prac raised swiss francs per tice adopted principles share nonvoting equity security followed compiling adjusted genussscheinif approvedthis figures listed groups fifteenth dividend adjusted basisnet income fell slightly increase many years billion swiss francsas im letter chairman provements groups operating changes introduced performance outweighed make annual report infor decline financial income mativefor exampledisclosures higher tax expensesthe groups expanded include profitability effective tax rate increased figures segment phar operating income accounted maceuticals divisionand considerably higher proportion also find detailed information pretax income case compensation paid members previous years board directors execu gain sale labcorp shares tive committee payments taxed united statesas made group statutory resultpretax income rose auditorsto ensure group opera net income taxes tions managed supervised focus creating value adjusted operating profit rose board directors established billion swiss francsthanks committees made nonexecutive sales gains pharmaceuticals members boardin diagnostics divisions signifi also reinforced framework cantly improved cost structure corporate governance roche expenditures productionmarket creating post compliance offi ing distributionand research cer ensure roches corporate development grew slowly principles adhered throughout salesthis largely result groupthe new post finance risk manager established meet requirements modern corpo groups cost structure improved rate governance finance area well significantly thanks restructuring process pharmaceuticals division pharmaceuticals division recorded prescription drug sales billion swiss francs includ pharmaceuticals divisions inggenentechthanks measures restructuring initiative reshaping initiated divisionstagnant future growthlaunched sales growth first quarter first half implementation followed three quarters initiative proceeded swiftly market gainsresulting fullyear socially responsible manner sales increase local curren ciesthe global pharmaceuticals expectednet financial income market grew last year decreased yearfalling bil lion swiss francsthis primarily division already achieved due downturn world finan substantial ongoing cost savings cial markets withits restructuring programme operating profit margin apart improved comparabil sales prescription medicines ity financial statementsother rose percentage points letter chairmanebitda ofthe pharmaceuticals divi nations world health orga sion totalled billion swiss francs nizationwe currently conducting ofsalescompared number programmes improve margin califor access antihiv medicines niabased subsidiary genentech also fortovase viracept people reported increase operating africa worlds least developed profitfuelled strong sales growth nationshoweverfor roche first year entire researchbased pharmaceuticals genentech contributed positively industrypatent safeguards fair groups operating results applying prices remain absolutely vital high international accounting standards roche became global market pharmaceuticals division five products annual sales leader important therapeutic area approximately billion swiss francs morethis represents significant oncology expansion revenue base recently rocephin levels investment discovery product sales magni development new medicines tudein roche became sustainedthanks global market leader important heavy rd commitmentfor exam therapeutic area oncologyours pleantihiv medicines belonging company offering three toa new class known fusion innovative new anticancer medicines inhibitors advanced stage oncology franchise development andonce approved accounts approximately one help counter growing prob fourth total prescription drug lem viral resistance toexisting sales hivtreatments growth topselling prod last months ucts offset losses generic focused research seven major competitors lower sales therapeutic areas pursuit antihiv medicines result ever effective treatments increased competition price conditions aidscancer reductionsduring year public alzheimers diseasediabetes discussion pharmaceutical patents strokeour expenditures research pricing focused particularly development reached billion aids developing emerging swiss francs last yearcounting market countriesin many countries optin rights new compounds howeverprevention programmes roches pharmaceuticals pipeline andthe task building adequate comprises total new molecular medical infrastructure still entitieswe currently pursuing receiving priority deserve development projectsinclud years roche actively ing work supplementary indica involved fight aids tionsin expect receive working closely united approvals tamiflu european letter chairman union pegasys europe increasing corporate consolidation united statesin additionwe among customers competitors submitting marketing applications andeven importantthe year major new medicines possibilities opportunities opened sequencing roche consumer healthour non human genome radically trans prescription medicines business forming diagnostics industry increased sales local background change currencies billion swiss francs roche diagnostics created solid operating profit margin platforms developing new business segment substantially modelstechnologies markets reported year alliances established beforethis marked improvement leading companies profitability resulted aggres accelerate strategic development sive focus eight key global brands roche diagnostics supplier clinically actionable healthcare diagnostics division expanded information already high share market reinforced position diagnostics likely first global leader invitro diagnostics industry even therapeutics sales rising local curren benefit scientific advances cies swiss francs ingenomics proteomicsroche billion swiss francsprofitability istherefore putting substantial measures also continued improve resources strengthening lead divisions operating profit molecular diagnosticsnotably ebitda margins advanced areas pcr applicationsblood percentage pointsrespectivelyto screening cancer testing licensing dispute igen united statesa lower court diagnostics first area benefit issued decision requiring roche pay total million dollarswe breakthroughs genomics file appeal deci proteomics sionwhich regard unjustified excessiveas previously reported roche took lawsuit divisions five business acquired boehringer mannheim areas grew faster market recorded provisions time contributed strong sales potential liabilitiesthe license agree performancethis balanced growth ment igen remain effect high baseline levels unique final legal decision reached industry underscores roche diagnosticsnumberone position vitamins fine chemicals globally key markets division posted sales billion united stateseurope asia swiss francs excluding medicinal feed additives business letter chairmandivested may divisional sales litigation resolved terms rose local currencies similar settlements already inswiss francswhile vitamins reached individual civil suits even greater extentcarotenoids thedivision also continued subject significant unbundling process begun several pricing pressuresthese offset years ago creating units whichto byincreased volume sales alarge extentare legally organi vitamins rising sales revenues sationally independentas result number productsparticularly major conditions place enzymes new product entries strategic realignment despite additional productivity divisionwe currently reviewing gainsoperating profit ebitda possible options decreased million swiss francs million francs strong diagnostics respectivelythis decline due pharmaceuticals divisions work primarily lower selling prices together wherever makes sense increases raw material medicalhealth economic com andenergy costs mercial terms critical future successlast year opened new division continues aggressively research building penzberg ger pursue measures improve many symbolises important productivity profitabilityit aims crossdivisional element roches halve cost producing key strategyit combines modern research vitamins within next years development facilities diag ensuring longterm ability nostics therapeutics sin defend global market leadership gle roofour aim medium term draw new research dis last year major strategic steps taken regarding future shape strong diagnostics vitamins businesswith con clusion proceedings euro pharmaceuticals divisions work together pean unionfollowing earlier antitrust action united states wherever makes sense medical two principal investigations health economic commercial terms pricefixing practices dating early vitamins industry critical future success brought closefurther progress also madeparticu larly recent monthstowards coveries provide range treat resolving outstanding suits filed ments closely tailored us customersadditional provisions needs individual patientsinte million swiss francs grated healthcare solutions tar recorded cover potential liabilities geted medicines benefit arising customer lawsuits patientsthey also help healthcare united statesthis amount based payers make optimum use avail assumption outstanding able funds letter chairman expect proposed alliance sales growth stable operating japans researchbased chugai phar profit ebitda marginsover maceutical announced late thenext three years expect important growth driver divisions operating profit margin alliance agreementchugai tomove towards japanese pharmaceuticals subsidiarynippon rochewill merge anticipate another year double roche acquire inter digit sales growth additional est new businessthe trans market share gains diagnos action significantly increase tics division divisions roches share japanese market operating profit margin increased second largest pharmaceuticals year market world beforeand next five years roughly novel business working raise slightly model japanese market still better subject approval chugais share holders antitrust authorities processes ofrenewal several countrieswe expect way divisions set stage transaction formally closed successful futurethe givaudan end spinoffthe acquisition ofa majority interest chugaithe review barring extraordinary eventsthe begun ofstrategic options roche group anticipates overall vitamins fine chemicals division sales growth current year andabove alltheimprovements mid high singledigit continually making operat rangewe expect see another small ing businesses allhave common goal improvement operating profit position roche innovative ebitda margins group strongly focused healthcare company levelgiven continued weakness delivers sustainable value financial marketswe anticipate patientsemployees shareholders marked decrease net finan cial income growth profitability pharmaceuticals division depend largely extent accutane experiences generic erosion going patent united stateshelped strong product franz bhumer portfoliothe rollout new prod ucts pegasys integra tion chugaiour pharmaceuticals business well positioned end year return mar ketlevel sales growth anticipate midsingledigit letter chairmanboard directors executive committee roche strengthened open annual general meeting elected walter frey serve remain transparent responsible management ing three years retiring member oversight group operations professor kurt jennys term board directorsjohn irving bell continue adhere principles nuffield professor clinical good corporate governance medicine university oxford elected boardhe succeeds franz b humer chairman board directors professor charles weissmannthe annual general meeting voted toelect franz bhumer another fouryear term board board directors directors annual general meeting april fritz gerber stepped board directorsthe executive chairman board committee employees directors roche holding ltdin roche thank fritz gerber long recognition outstanding contri exceptional record service butionsthe board directors wealso owe thanks former named fritz gerber honorary chair cantonal councillor kurt jenny man rochehe continue professor charles weissmannwho serve member board contributed greatly companys directorsthe board elected chief growth executive officer franz bhumer successor board directors executive committeeboard directors january left walter frey john bell andres f leuenberger andreas oeri franz b humer andr hoffmann rolf hnggi henri b meier fritz gerber peter brabeckletmathe name year birth term ends board directors dr franz b humer chairman dr andres f leuenberger cid vicechairman rolf hnggi cid cid vicechairman dr hc fritz gerber honorary chairman peter brabeckletmathe cid andr hoffmann cid cid prof dr john bell cid dr henri b meier dr andreas oeri cid walter frey cid secretary board directors dr gottlieb keller compliance officer franz b humer stellt sich fr eine weitere amtsperiode als verwaltungsratsmitglied zur verfgung cid finance investment committee fritzgerber wird auf die generalversammlung als prsident zurcktreten der verwaltungsrat cid audit committee hat franz b humer vorbehltlich wiederwahl durch die generalversammlung zum neuen cid remuneration committee verwaltungsratsprsidenten gewhlt fritz gerber gehrt nach seinem rcktritt als prsident weiter hin dem verwaltungsrat january kurt jenny tritt zurck und charles weissmann stellt sein amt auf die generalversammlung als verwaltungsrat zur verfgung walter frey und john bell werden der generalversammlung zur wahl den verwaltungsrat vorgeschlagen board directors executive committee current terms ofvicechairman evaluation candidates rolf hnggi peter brabeck executive committee letmathe members board directors end annual audit committee general meeting shareholders committee assists board theboard propose annual directors overseeing manage general meeting ment ofthe groups businessespartic elected additional four years ularly respect financial legal regular period office specified matters compliance internal articles incorporationin business administrative policies additionthe american economist including policies safety envi deanne julius german politi ronmental protectionin executing cal scientist horst telschikchairman responsibilitiesthe committee quandt foundationwill reviews scope extent ofexternal nominated election board internal auditsthe independence objectivity ofthe auditors board committees theestablishment ofappropriate orga corporate governance roche nisational structures safety servesto ensure management environmental protection oversight group operations conducted responsibly finance investment committee focus creating valuethe board finance investment committee directors delegated certain mat assists board issues relating ters four committees detailed financeinvestment capital assets attention prior referral full including evaluation risks boardthey presidium areasspecificallythe commit board directors comprising tee reviews chairman vicechairmen boardthe audit committeethe accounting systems procedures finance investment committee organisation scope andthe remuneration committee financial controlling financial planningbudgets auditfinance investment budget execution remuneration committees financial reporting shareholders composed three board members general public members execu financial investments tive committee remuneration committee presidium board directors upon application chairman chairman two vicechairmen remuneration committee serve jointly nomination com approves groups compensation mitteein capacity prepare policy compensation received proposals board directors members executive com regarding appointment new mitteegeneral managers major board members concerned roche affiliates highlevel succession planning employeesin additionit approves board directors executive committeeexecutive committee january front row left erich hunziker franz b humer markus altwegg back row left william burns richard laube heino von prondzynski daniel villiger jonathan knowles name year birth position executive committee dr franz b humer chief executive officer dr erich hunziker chief financial officer controlling william burns pharmaceuticals division heino von prondzynski diagnostics division dr markus altwegg vitamins fine chemicals division richard laube roche consumer health prof dr jonathan knowles global pharmaceutical research dr daniel villiger corporate services secretary pierre jaccoud executive committee statutory auditors ernst young ltd roche holding ltd group auditors pricewaterhousecoopers ag january board directors executive committee employee option programmes million swiss francs services equity profitsharing renderedthey also paid mil devices defines general policy lion swiss francs additional audit oncompany pension benefits ing services million swiss francs postemployment benefit plans tax advice million swiss francs consulting services compensation members board statutory auditors ofroche directors receive annual compensa holding ltd various subsidiaries tion swiss francs ernst young ltd received serving onthe boardthe compensa swiss francs services rendered tion paid chairman deducted anda swiss francs hisagreed salarymembers forother advisory servicesernst serving board committees receive young ltd also acts independent additional compensation auditors genentechincfrom swiss francs time received million swiss francs expenses genentechs security exchange commission audit additional members executive compensation million swiss committee received fixed salaries francs separate services totalling swiss francs variable bonuses totalling compliance officer swiss francs total early board directors stock options priced swiss roche holding ltd voted create francs position compliance officer thecompliance officer responsible optionswhich maynot exer ensuring roches corporate cised three yearsentitle holders principles consistently adhered topurchase roche nonvoting equity throughout grouphe also securities genussscheineat ratio contact person shareholders price swiss francs employeescustomerssuppliers eachthe options traded general public issues relating stock exchange may exercised groups corporate principles april december good corporate governancein valued swiss creating positionthe board francs eachthe options directors underscored impor underlying nonvoting equity securi tance attaches high standards ties held reserve bought area integrity roche thestock market programme board directors appointed result inadilution gottlieb keller compliance officer value roche securities gottlieb kellerwho holds post continuing serve secretary relationship group auditors board directorsreports andstatutory auditors directly tothe chairman board group auditorspricewaterhouse make regular reports coopers ag received compensation boards audit committee board directors executive committeeexecutive committee effective october board directors appointed erich hun ziker executive committee roches new chief financial officer succeeds anton affentrangerwho left roche mayerich hunziker yearold swiss national holds phd industrial engineering federal institute technol ogy zurichfrom erich hunziker held various leading positions finance areathe diagnostics pharmaceuticals busi ness boehringer mannheim last became chief financial officer corangebefore joining rochehe served chief executive officer diethelm kelleran international trading group based zurich companys articles incorporation found wwwrochecom board directors executive committee heart transplant saved marcel ss life roches cellcept making sure body reject new heart continue volunteer work swiss heart lung trans plant association les de cur aces hearts roche established foundation support research transplantation medicine roche organ transplan tation research foundation currently supporting large number studies universities transplant centres research institutespharmaceuticals division brief millions chf change sales prescription otc ebitda operating profit rd expenditures employees including genentech adjusted basis pharmaceuticals difficult start first three months sales prescription medicines grew faster global market last three quarters growth fuelled primarily extremely successful oncology franchise number leading products compensated lost sales resulting expiry us patent verseddormicuman important milestone reached launch pegasys hepatitis c first markets restructuring programmereshaping future growth accelerated growth prescription drug sales reducing costs last year already positive impact profitability pharmaceuticals business december roche chugai announced alliance create leading researchdriven pharmaceutical company japan roche hold majority interest company rank fifth sales worlds second largest pharmaceuticals market pharmaceuticals profit margin ofafter margin divisions ebitda totalled million swiss francsor ofsalesand thus percentage points higher year beforethis improvement profitability areflection ofhow successful ourreshaping future growthinitiative beenit achieved despite aonetime gain million swiss francs recorded thesale ofthe north american rights coreg prescription pharmaceuticals strong growth oncologytotal pre scription drug sales including genen tech increased million swiss francsfor yearonyear growth rate local currencies swiss francson adjusted basis operating profit prescription restructuring initiative business reached million swiss francsthis equivalent reshaped division future growth ofsalescompared improved divisions performance ebitda totalled million swiss francsor ofsalescompared terms sales profitability moreover margin roche become oncology power excluding genentechprescription house successfully introduced drug sales rose million swissfrancsfor growth rate innovative hepatitis c medicine pegasys local currencies swiss francs adjusted basisoperating profit various markets totalled million swiss francsthe william burns head pharmaceuticals division operating profit margin margin previous year ebitda reached million swiss pharmaceuticals sales francs andwas equivalent profitability increasedsales salescompared pharmaceuticals division rose local currencies swiss francs genentechs sales improved million swiss francs million swiss francs adjusted basisoperating profit local currencies swiss reached million swiss francs francsoperating profit totalled equivalent operating million swiss francsthis equiva pharmaceuticalslent ofsalesup nega total divisional sales millions chf tive operating profit margin turnaround resultofstrong sales growth came despite higher costs incurred increase salesebitda increased million swiss francs andwas ofsales slightly prior year level prescription sales growth roche andgenentech led ouroncology portfoliowhich accounts ofour prescription drug businesslast year roche faster marketthanks primar becamethe global market leader ily successful launch ofour two key therapeutic areamoreover important cancer medicines roche company three bycontrastsales europe showed new oncology products herceptin midsingledigit growthin latin xeloda mabtherarituxan america sales contracted roughly whichhave shown clinical rate market whole trials improve patient survival owing price reductions antihiv major growth drivers included medicinesand macroeconomic prob cellceptwhich used transplan lems regionsales advanced tation medicineand anemia treat bydoubledigit percentages ment neorecormonthe antibiotic regionsfuelled primarily rocephin xenicalour leading launch ofxenical major asian weight loss medicationalso posted markets growth oncology roche moves growth products lead portfolio innovative offset losses due expiry medicines canceroncology ofour verseddormicum patent one ofthe therapeutic areas theunited statesthe delisting currently inno draganon japan price reduc vativeit also area tions antihiv productswhich strongest growthtotal sales ofour weresubject increased competitive cancer medicines increased pressures price erosion million swiss francs theyear making roche worlds leading sup plier key therapeutic areathe sales ofprescription medicines innovative biotechnology products north america showed doubledigit herceptin andmabtherarituxan gain ofthanks strong sales ledthis strong performancewith growth genentechin japanthe majorcontribution also coming worlds second largest pharmaceuticals xelodaa novel tumourselective marketsales grew four times treatment pharmaceuticals sales ofmabtherarituxanthe first primarily launches western humanised monoclonal antibody europe japan brisk sales treatment ofcanceronce inthe united statesthis monoclonal doubledrising million swiss antibody shown signifi francsin drug approved cantly increase survival breast japan use indolent non cer patients overexpress hodgkins lymphoma nhlnhl agene associated aggressive frequent form ofblood cer cell growth cermabtherarituxan also shown improve survival xeloda sales also rose sharplyadvanc patients aggressive nhla faster ing local currencies mil growing form ofthe cancer affects lion swiss francsthis oral anticancer halfofall nhl patients agent activated inside cancer cells inoctober european committee delivering effective chemotherapy proprietary medicinal products cancer cells sparing healthy ones prescription products including genentech metabolic japan others disorders others latin america dermatology central nervous system oncology sales region sales therapeutic area infectious diseases virology north america europe cardiovascular diseases inflammatory autoimmune diseases cpmp issued positive opinion xeloda approved use ofmabtherarituxan markets metastatic breast new indicationadditionallythe drug colorectal cancers potential investigated potential use many types ofcancer inautoimmune diseasesmabthera eu us approvals colorectal rituxan also undergoing phase ii cancer received february clinical testing combination mayrespectivelyxeloda recently chemotherapy agent fludara approved united states berlexinitial positive results usein metastatic breast cancer already obtained patients taxotere aventisthe cpmphas previously untreated chronic lympho also recommended european approval cytic leukemia ofxeloda singleagent ther apy combination taxotere sales ofherceptin grew combined chemotherapy signifi local currencies million swiss cantly improves survival inmetastatic francsthis sharp increase driven breast cancer pharmaceuticalstarceva promising new anticancer agent developed roche genentech partnership osi pharmaceuticalspreparations phase iii clinical testing nonsmall cell lung cancer already begun additional phase ii phase iii trials currently way several indicationsthis novel oncol ogy product potential effective range ofdifficulttotreat cancerssuch lungovarianbreast colorectal cancer supportive carekytrila bondronat thirdgeneration bis potent antiemetic used control phosphonate management nausea vomiting patients hypercalcemia abnormally elevated undergoing cancer chemotherapy serum calcium caused cancer posted sales million swiss afiling europe use metastatic francs first full year since bone disease breast cancer patients acquired rochein united planned states marketing application filed last year use ofkytril transplantation continued strong inpostoperative nausea growthroche strongly committed vomiting improving longterm outcomes oftransplantation enhancing sales ofthe recombinant growth factor quality oflife oftransplant recipients neorecormonwhich stimulates groups transplantation portfolio production ofred blood cellsrose generated total sales million local currencies reached swiss francs increase million swiss francsalthough year anemias associated poor kidney function still main sales driver cellcept establishing itselfas considerable growth also come cornerstone ofeffective longterm use ofthe drug hematological immunosuppressive therapy prevent cancersan indication approved rejection oforgan transplantssales europe last yearthe established substantially year role ofneorecormon nephrology rising local currencies strengthened european million swiss francsthe potency approval ofa newonceweekly dosing cellcept makes possible reduce schedulethe product currently use ofmore toxic immunosuppres inclinical trials todetermine whether sive drugsunlike products suitable supportive cancer cellcept toxic kidneys therapy patients solid tumours increase risk ofcar improvedsecondgeneration diovascular disease benefits product also development result longer transplant patient pharmaceuticals survivalcellcept approved francslaunches inmajor asian mar europe last year use children kets helped grow salesas following kidney transplantation focused marketing strategy puts greater emphasis patient support zenapaxwhich used combina satisfaction contributed tion cellcept prevent acute stabilising sales united states kidney transplant rejectionposted increased sales achieved sig sales million swiss francssales nificantly lower costxenical ofcymevenecytovenean antiviral available weight loss medication works locally gastrointesti nal tractwhere reduces absorp tion ofdietary fat around additionoverweight type diabetics treated xenical clinical trials found lose significantly weight treated diet aloneapproximately ofpeople type diabetes overweight excess weight impor tant modifiable risk factor develop ment ofthiscondition virology major innovationsin roches important virology port agent used hiv care folio strengthened transplantation treat prevent approval ofpegasys hepatitis c eyeinfections caused cytomegalo first marketsswitzerlandmexico virus cmv retinitis including sales venezuelathis newgeneration ofits oral formulation valcytegrew pegylated interferon potent medi valcyte launched cationproviding sustained virus sup united states treat cmv pression one dose week retinitis hiv patientseuropean clinical trials shown restofworld approvals number ofpeople virusfree expected first quarter six months treatment stopped onwork also way higher pegasys amarketing application use singleagent therapymoreover transplantationwhich expect combined therapy pegasys submit later year ribavirin shown clearly effective regimen xenical leading medicine without compromising tolerability weight loss weight control approvals single xenical worlds leading prescrip agent combination therapy tion product treatment ribavirin including roches obese overweight patientssales ribavirin expected mid ofxenical rose moderate europe towards end local currencies million swiss ofyear united states pharmaceuticalsmajor product approvals launches product generic name indication country roaccutane accutane isotretinoin severe acne pediatric exclusivity usa cellcept mycophenolate mofetil prevention acute rejection pediatric kidney transplantation eu herceptin trastuzumab metastatic breast cancer japan eu mabtherarituxan rituximab indolent nonhodgkins lymphoma japan neorecormon epoetin beta weekly anemia chronic renal failure eu anemia patients hematological malignancies eu pegasys pegylated interferon alfaa hepatitis c switzerland mexico venezuela tamiflu oseltamivir treatment influenza b japan valcyte valganciclovir cytomegalovirus infection immunocompromised patients usa xeloda capecitabine metastatic colorectal cancer usa eu xeloda taxotere capecitabine docetaxel metastatic breast cancer usa eu includes supplemental indications updated midfebruary patent extension february based pediatric data sales oftamiflu increased local though class ofmedicines currencies million swiss francs still mainstay ofmany antihiv despite modest sales treatment regimenssales declined last canbe attributed last years year local currencies mild flu seasonthe product estab mounting competitive pressure lished itselfas market leader newly launched antihiv medicines tamiflu successfully launched price reductions provided japan early marketing developing countries improve access application also filed important drugs accounted pediatric formulationapproval drop sales revenuesales europe treatment pre proteaseinhibitors expected vention ofinfluenza b adults stabilise volume growth adolescents children expected partially offsetting continued low prices viraceptfortovase invirasethe together trimerisroche protease inhibitors core developing tthe first ofa new hiv portfoliogenerated com class ofmedicines known fusion bined sales million swiss francs inhibitorsunlike existing hivaids pharmaceuticals topselling prescription products including genentech change sales change local product generic name indication millions chf chf currencies rocephin ceftriaxone bacterial infections mabtherarituxan rituximab nonhodgkins lymphoma roaccutaneaccutane isotretinoin severe acne cellcept mycophenolate mofetil transplantation xenical orlistat weight loss weight management herceptin trastuzumab metastatic breast cancer neorecormon epoetin beta anemia viracept nelfinavir mesylate hiv infection kytril granisetron chemotherapy radiation therapyinduced nausea vomiting nutropin protropin somatropin somatrem growth hormone activase tnkase alteplase tenecteplase myocardial infarction pulmozyme dornase alfa dnase cystic fibrosis neupogen filgrastim gcsf neutropenia furtulon doxifluridine cancer colon breast stomach cymevenecytovene ganciclovir cytomegalovirus infection valcyte valganciclovir dilatrend carvedilol heart failure hypertension angina pectoris lexotan bromazepam anxiety tension states xeloda capecitabine colorectal breast cancer madopar levodopa benserazide parkinsons disease rocaltrol calcitriol osteoporosis inhibace inhibace plus cilazapril hypertension torem torasemide hypertension roferona interferon alfaa hepatitis b c cancer invirase fortovase saquinavir hiv infection rivotril clonazepam epilepsy dormicumversed midazolam anesthesia sedation jointly marketed roche genentech four products posted sales billion swissfrancs half divisions top tenproducts showed doubledigit sales growth sales anticancer drug mabtherarituxan doubled making roches second best selling pharmaceutical behind antibiotic rocephin pharmaceuticalsdrugswhich work inside host cells products even though sales target viral enzymes involved declined local currencies hiv replicationt inhibits million swiss francs fusion ofhiv host cellsthus dual pressures ofgeneric competition blocking virus enters cells number ofmarkets begins replicatet restrictive prescribing environment expected offer new therapeutic united statesthe product may option pretreated patients face challenge generics hivincluding infected united states patent expires drugresistant strains ofthe virus spring although approximately patients previ anticipate downturn salesits ously treated antihiv magnitude depend ability medications currently participat ofgeneric manufacturers replicate ing phase iii trials evaluate stringent safety programmes novel medicineifthe clinical trial put placein close cooperation results positive expectedand food drug administra sophisticated production facilities tion fdato ensure safety required manufacture complex patients undergoing treatment peptide completed schedule accutaneroaccutane regulatory filings sub mitted united states europe dilatrendan agent proven across second halfof entire spectrum ofheart failure condi tions far effective con established products newcom ventional betablockersachieved dou ers high potentialrocephin bledigit growthwith sales totalling leading antibioticremains million swiss francsgrowth drug ofchoice treating bacterial fuelled publication oftwo infections hospitalssales ofthe landmark trials investigating drug product year insevere chronic heart failure post advancing local currencies myocardial infarction patientsdata million swiss francsthanks shown dilatrend confer highly oncedaily convenience contin significant survival benefitin addition ued effectiveness broad range substantially reducing hospitalisa ofpathogensrocephin sales grew tions improving patientsquality despite generic competition num liferoche pursuing supplemental ber ofmarketsrocephin remain approval ofthe drug use patients akey contributor roches prescrip severe chronic heart failure tion drug sales strong sales united states bonviva highly effective bisphos product go offpatent phonate developed treat italy compensating generic erosion ment prevention ofosteoporosis elsewhere great market potential scored late announce roaccutaneaccutanethe effec ment roche glaxosmithkline tive treatment available severe agreed codevelop copro acneremained one ofour bestselling mote productlatestage clinical pharmaceuticals testing ofthe drug already operating profit marginwhich completed shows bestinclass climbed adjusted basis reduction risk ofvertebral frac singledigit figure turesbonviva first bisphospho last year increased nate proven ability reduce adjusted operating profit reached fracture risk even ifpatients take million swiss francsfor increase week drug holiday quarter ofebitda adjusted grew initial regulatory filings europe million swiss francs united states planned equivalent ofsales compared sales continued grow ahead ofthe otc marketwhich stagnant overallsales showed modest gain local currencies slightlydeclined swiss francs terms slipping million francs excluding markets experienced significant macroeconomic difficulties year argentinabrazil turkeyresulting drop salesrch posted sales growth local currenciesthis increase came despite elimination ofthe resale price roche consumer health focuses brands maintenance system united kingdoma change adversely clear benefit consumers impacted results europe future growth working sales vitamin segment declined exciting new business models area local currenciesroughly line aging weight management market trends segment core redoxon supradyn richard laube head roche consumer health brands hit particularly hard economic downturn several countries market roche consumer health leadersand low incidence roche consumer health rchs offluand colds throughout much tenth year ofoperation saw con ofeurope also negative impact tinued progress creating strong onsales brandsover years rchs eight key global brands averaged annual significant progress made growth today account analgesics segmentmore offset nearly ofour nonprescription ting lower sales ofvitamin products otc salesby focusing aggressively continued sales growth aleve profitable growthsince itsfound especially united statesfurther ing rch significantly improved market expansion europe pharmaceuticalssuccessful rxtootc switches consumer selfmedication naproxenbased brands latin america contributed success another highlight continued skin hair care sales growth ofour bepanthen skin analgesics gastrointestinal products care brandfollowing successful others relaunch europethe brand sales therapeutic area cold remedies expanded markets vitamins research development highly promising pipelinethe signif icant investments pharmaceuticals division made creating groupwide process moves proj focus eight global otc brands ects seamlessly research devel change sales change local opment marketing starting product uses millions chf chf currencies tobear fruitthanks increased pro aleve naproxen analgesic ductivitythe division supradyn multivitamin pipeline ofimportant new medicines bepanthen skin care highly promising terms rennie antacid ofboth quantity quality redoxon vitamin c ofprojects berocca multivitamin saridon analgesic division pursuing total elevit pronatal multivitamin research projects seven key therapeutic areasoncologymetabolic disordersinflammatory diseases genitourinary diseasescentral nervous total ofover projects pur system disordersvascular diseases suedincluding supplemental indica virologyin ofthese areas tionseleven nmes earlystage significant unmet medical needs phase developmentsix commercial potential entered phase clinical testingeight products addressing needs phase iiand five phase iii correspondingly highwith new pharmaceutical pipeline molecular entities nmes reaching strengthened optin rights addi preclinical development tional nmes agreements roche leader pharmaceutical genentech basilea pharmaceutica research productivityseveral ofthese potential new medicines projects could enter phase clinical genentech commercialise testing alone partiesincluding rocheexpects additional nmes theseadditional compoundsthere enter preclinical development nmes roche pipeline currently nmes moreoveronce transaction divisions development pipelineand chugai closedroche pharmaceuticals right license projects research projects major therapeutic areas chugai seeks partner outside japan south koreachugais rd focus oncology bonerenal cardiovascular diseasesand metabolic diseases expect toyield number ofcom virology oncology vascular diseases pounds suited global development marketing genitourinary diseases inflammatory diseases successful research unit central nervous system kamakura japan merged chugais research organisation strengthening japanese companys innovative capabilities gene drug discovery collabo ration decode genetics produced breakthrough findings last yearnew targets identified analysing genes linked two common diseases schizophrenia periph eral arterial occlusive disease basis drug diagnostic discovery programmea gene contributes stroke also identifiedand researchers decode mapped chromosomal loca new knowledge molecular tions ofgenes linked type dia betesobesity clinical anxietythe pathology human disease mapping ofthe first gene linked opening new opportunities creating torheumatoid arthritis provide genetic markers predict novel medicines diagnostics scientists increased risk ofdeveloping dis roche taking lead using new easeall achievements mark important early steps towards turning global multidisciplinary approach discoveries genomics dramatic improvements healthcare turning data specific knowledge allows us invent really important part ofefforts streamline research organisationthe pharmaceu new medicines future ticals division discontinued research activities welwyn united jonathan knowles head global pharmaceutical research kingdomwelwyns viral diseases research unit transferred palo alto united statesstrengthening highly productive sitewhich also pharmaceuticalsfiled solid pipeline indication therapeutic area projectproduct type generic name major line extension phase phase phase ii phase iii phase iv anemia r next generation anemia treatment renal anemia cancerrelated anemia neorecormon glycoprotein epoetin beta needlefree injection system radiotherapy anemia prematurity weekly oncology inflammationbone r nuclear receptor modulator osteoporosis r kinase inhibitor rheumatoid arthritis rbonviva bisphosphonate ibandronate treatment osteoporosis mabthera monoclonal antibody rituximab rheumatoid arthritis metabolism r nuclear receptor modulator type diabetes r gpcr modulator obesity r enzyme activator diabetes r insulin sensitizer type diabetes xenical lipase inhibitor orlistat development japanc pediatric indication prevention diabetes treatment diabetes nervous system r gpcr modulator depression r gpcr modulator depression anxiety r gpcr modulator depression anxiety oncology r enzyme inhibitor solid tumours r gpcr modulator emesis r kinase inhibitor solid tumours r monoclonal antibody solid tumours r cell cycle inhibitor solid tumours rtarceva kinase inhibitor solid tumours r pegylated recombinant protein gcsf pegylated filgrastim chemotherapyinduced neutropenia rpegasys pegylated interferon peginterferon alfaa malignant melanoma bondronat eubonviva us bisphosphonate ibandronate metastatic bone disease breast cancer herceptin monoclonal antibody trastuzumab joint development activitiesc rochesponsored activitiesc mabthera monoclonal antibody rituximab aggressive nonhodgkins lymphoma xeloda capecitabine firstline combinations metastatic breast colorectal cancers adjuvant monotherapy combinations colon rectal breast cancers respiratory r integrin antagonist asthma r integrin antagonist asthma r nuclear receptor emphysema r nuclear receptor emphysema transplant valcyte nucleoside analogue valganciclovir prevention cytomegalovirus infection solid organ transplantation cellcept impdh inhibitor mycophenolate mofetil acute renal transplant rejection urology r gpcr antagonist benign prostatic hyperplasia r gpcr antagonist overactive bladder pelvic hypersensitivity r gpcr antagonist stress urinary incontinencevirology r protease inhibitor hiv infection rlevovirin new generation nucleoside analogue hepatitis c r fusion inhibitor hiv infection r fusion inhibitor hiv infection rpegasys pegylated interferon peginterferon alfaa chronic hepatitis c pegasys pegylated interferon peginterferon alfaa hepatitis b pegasys ribavirin peginterferon alfaa ribavirin chronic hepatitis c roche ribavirin pegasys ribavirin peginterferon alfaa roferona interferon alfaa chronic hepatitis c valcyte nucleoside analogue valganciclovir treatment cytomegalovirus retinitis patients aids fortovase protease inhibitor saquinavir pediatric formulation tamiflu neuraminidase inhibitor oseltamivir treatment prevention influenza viracept protease inhibitor nelfinavir mesylate hiv infection new formulation optin opportunitiesa basilea pharmaceutica bal antifungal fungal infection bal antifungal fungal infection bal antibiotic bacterial infection bal nuclear receptor plaque psoriasis bal cisretinoic acid chronic hand eczema pozen mt gpcr modulator migraine speedel r endothelin receptor antagonist cardiovascular disease genentech trastuzumabdm antibody solid tumours antitissue factor monoclonal antibody fragments acute coronary syndrome amd fab monoclonal antibody fragment agerelated macular degeneration ldp antibody monoclonal antibody inflammatory bowel disease avastin antivegf antibody avastin solid tumours chemotherapy participation genentechb e antiige antibody allergic asthma allergic rhinitis thrombopoietin protein thrombocytopenia xanelim anticda antibody psoriasis xolair antiige antibody allergic asthma anticda antibody anticda antibody solid organ transplant rejection external partners genentechosi phase trials currently preparation pharmaceuticals division currently nmes development pipeline eleven earlystage shearwater amgen phase ii trials currently preparation development phase six entered phase clinical testing eight phase ii five phase iii genetics institute icn roche retains right license product total projects pursued including supplemental indications nmes genentechidec trimeris b full consolidation roche pipeline vernalis gilead c competitive reasons projects may genentech agouron identified phase transition preclinical clinical development phase initial studies healthy volunteers phase ii smallscale efficacy tolerability dosefinding studies patients bluetype represents new molecular entities nmes phase iii largescale studies patients statistical confirmation safety efficacy current january phase iv data longterm efficacy effects following marketing approvalfocuses discovery early added impetus growth clinical development ofnew medicines expected come merger inflammationrespiratory diseases nippon roche chugaiannounced bone disordersneurobiological disor late mergerwhich ders genitourinary diseasesthis create novel business model step underscores roches commitment japanese marketis still subject maintaining strong presence approval bychugais shareholders areas ofhivaids hepatitis antitrust authorities several countriesthe necessary approvals outlookthe pharmaceuticals division anticipated fourth quarter currently expects see midsingle digit sales growth signifi cant extentsales performance helped strong product portfolio beinfluenced soon accutane rollout ofnew products roaccutane faces generic competition integration ofchugaiour pharmaceu us marketthe division ticals business well positioned focus particular driving end ofthis year return oncology franchisewhile strengthen marketlevel sales growth ing position therapeutic objectivewhich expect achieve areas wellwe anticipate continued next three yearsis increase doubledigit sales growth operating profit margin leading anticancer drugsnotably pharmaceuticals division herceptinmabtherarituxan present level towards xelodathese three medicines neorecormon currently investigated useinnew indications approval ofmabtherarituxan aggressive nhl double poten tial patient population eligible treatment medicinewe also looking growth leading roche productssuch cellceptdilatrend xenicalwe anticipate approvals tami flu european union pegasys europe united statesmarketing applications bonviva united states europefor bondronat europe pegasys japan important filings planned additionallyapprovals anticipated number ofimportant line exten sions new indications existing products pphhaarrmmaacceeuuttiiccaallss clinical practice getting right diagnosis quickly decisive using roche lightcycler prof ms laboratory perform variety genetic tests deliver diagnostic information fast helping doctors make right treatment decisions roche supplies innovative system technologies genomics proteomics research main focus developing new applications pcrbased diagnosticsdiagnostics division brief millions chf change sales diabetes care near patient testing centralized diagnostics molecular diagnostics applied science ebitda operating profit rd expenditures employees diagnostics roche diagnostics posted doubledigit growth rates well market averageas result division expanded lead market segments national markets serves rollout new products customers ranging highworkload laboratories individual consumers positive impact sales divisions operating profit margin also showed yearonyear gain position strength roche last year implemented major initiatives pointing way forward new dimension medical diagnosticswith business areas focused tightly customers roche diagnostics even responsive market needs alliance icelands decode genetics develop new genebased diagnostic systems marks another important step roche road individualised healthcare diagnostics profitability measures also continued improveoperating profit increased million swiss francswhile ebitda advanced million swiss francsthe divisions operating profit margin rose percentage points ebitdamargin percentage points strong sales growth offset increased costs incurred yearparticularly marketing distributionas well new strategic alliances licenses apart expertise high growth areas molecular diag nostics dataassisted patient self managementa number attractive new products contributed last years solid performancethese included accuchek compact sys tem blood glucose selfmonitoring consumer diagnostics segment challenge face continue e modulewhich adds immunoassay capabilities cost grow faster marketas market savinghighthroughput modular leader roche diagnostics shape analytics system used largevolume laboratories market ways build strengths focus business even diagnostics division file anappeal court judgement sharply customersneeds awarding igen international million dollars compensatory dam heino von prondzynski head diagnostics division ages million dollars puni tive damages inlitigation brought igen united statesthe litiga increased sales profitability tion concerns claims relating sales local licensing igens electrochemilumi currenciesroche diagnostics nescence ecl technology roche outpaced market substantial diagnostics marginsales advanced mil lion swiss francsreinforcing divi strong sales growth regions sions position world leader sales double invitro diagnosticsroche holds digit percentages growing signifi share global market cantly faster market diagnosticsfive geographic regions total divisional sales millions chf division businessthe largest increase came japanwhere sales advanced north america gains reported strategi cally important product lines market segmentsineurope bse test marketed division particularly strong growth driver increased sales iberialatin america due primarily divisions strong service offerings highperformance solutions aimed serving needs laboratoriessales genebased tests health professionals linked accounted formuch robust together new lab network growth japanthe establishment organisationthese three business roche diagnostics shanghaiopening areas complemented applied direct access highgrowth sciencewhich supplies universities chinese marketwas key factor industry reagents sys healthy sales increase tems research projects reported asiapacific region also serves division breeding ground new technologiesand uncompromising customer focus diabetes carewhich focuses exclu new role medicinethe diagnos sively diabetes market tics industry midst tran sitionas customers competitors established supplier leading strive grow businesses instrumentsreagents services mergers acquisitions roche diagnostics also increasingly knowledge continues grow becoming pioneer providing exponentially following mapping sophisticated solutions support human genomeitand ecom themthe main focus diagnostic mercewhich also steadily gaining information management tools importance diagnosticsare assist therapeutic decisionmaking another force change almost realtime linking interpreting new stored patient diagnostics division data responded challenges comprehensive strategic realignment number partnerships created solid platforms alliances also helping division forthe development new business implement strategic visiona modelstechnologies markets licensing agreement chiron opens opportunities division divisions centralized diagnos enhance strong interna ticsmolecular diagnostics near tional presence blood plasma patient testing businesses screening becoming supplier diagnostics pcrbased products blood networkable accuchek bank marketthe alliance inform system hospitalsroche digene broadened portfolio diagnostics leading supplier tests sexually transmitted dis professional diabetes monitoring eases oncologyan agreement systems worlds largest market innogenetics offers opportuni ties roche establish presence diabetes care already working diagnostic microbiology next generation ofaccuchek pcrbased testsand cooperation compacta totally new type decode enable us tap devicecombining digital organiser thetremendous potential genetics blood glucose meteris also near genomics ing launchthe device features japan others near patient testing applied science asiapacific europe molecular diagnostics sales region sales business area north america diabetes care centralized diagnostics iberialatin america business areas growth track infrared data port makes easy diabetes care roche dia patients keep comprehensive betes care one log readings downloading divisions successful business data systems areaswith sales local currencies research diabetes care goes far beyond developing everbetter glucose sales ofaccuchek advantagethe metersfor examplewe searching worlds topselling blood glucose ways measure blood glucose meter patient selfmonitoring without take blood sam another autumn pleone result efforts two major new products accuchek dtectorwhich diag launched north americaaccuchek nose type diabetes bymeasuring compactwhich features integrated changes eyesa largescale test strips automatic coding clinical trial deviceis cur pretest checks strip integrityand rently wayour researchers accuchek activewhich perform arealso investigating continuous measurements five seconds monitoring techniques could tiny blood samplethe market employed artificial pancreas response products measures blood glucose levels goodwe expanded delivers insulin doses lead us market launch bodywhen needed diagnosticsto augment research activities roche diagnostics leader uri diabetesroche acquired califor nalysis multiparameter systems niabased amira medical november giving solid presence grow companys knowhow ing primary care segmentresearch patent portfolio greatly facilitate development segment roche diagnosticsaccess fast aimed developing newgeneration growing integrated spot monitoring instruments substantially segment diabetes market smaller powerful data management capabilities near patient testingsales roche currently available near patient testing supplier products services doctors roche near patient testing officesambulances intensive care leading supplier coagulation units last year local monitors patient usewith currenciesmaking one divi coaguchek system paved sions fastest growing business areas way duplicating tremendous helped successful integration success roches accuchek dia medical instruments business betes products coagulation acquired austrias avl monitoring segment groupwe accelerated market share growth hospital pointof care segment rapid diagnostic prod ucts emergency roomsintensive care units hospital set tingsroche diagnostics consoli dated leading position seg ment rollout omni c blood gas analyser fourth quar ter omni opti plus two additional systems blood gas electrolyte measurementare expected reach market mid future hospital pointofcare centralized diagnosticsroche cen testing lies linking testing tralized diagnostics leader devices electronically hospitals integrated analytical systems hos laboratoriescentral data man pitals highvolume service labo agement systemsaccordinglywe ratoriesits main areas concentra focusing research activities tion system networking developing innovative solutions process optimisationsales rose like datacare linewhich allows year local currenciesa solid complex test data managed result business areas fiercely exchanged ease competitive market diagnostics centralized diagnosticselecsys license agreement igen immunodiagnostic systems achieved remain place final judge increase salesa significant ment reachedthe division growth driver e module continue develop new tests makes possible per elecsys systemsand also con form highthroughput immunochem tinue market instruments tests ical testingdeveloped record covered licensing agreement including e system broadest pipeline diagnostics industry research efforts centralized diag nostics focused tradi tional core areasas part roches crossdivisional proteomics initiative diabetes care searching new markers applied science used early detection near patient testing monitoring various types major innovations expected business areas within next five years cancer metabolic inflamma tory diseasesin additionan agree centralized diagnostics molecular diagnostics ment signed january mil lennium collaborate developing markers rheumatoid arthritis time six monthsthe e module covers broad spectrum molecular diagnosticssales diagnostic applicationsin addition roche molecular diagnostics two elecsys blood tests prostate increased local currencies cancer received us regulatory underscoring strength field approval launch genetic testinggrowth fuelled diagnostic marker early detec primarily demand pcrbased tion heart failure impor products servicespcr poly tant addition roche diagnostics merase chain reaction molecular product portfolio cardiovascular biology technique capable produc disease ing millions copies specific dna sequences short timethus hematology centralized diagnos making possible diagnose dis tics posted abovemarket growth eases quickly reliablypcr helped alliance japan based tests transmissible diseases based sysmexthe new xe fungal infectionsparticularly hematology analyserlaunched tests hepatitis c hivaids well received market accounted substantial portion placecentralized diagnostics suc sales cessfully defended share blood coagulation monitoring july molecular diagnostics automated urinalysis segmentscar received us regulatory clearance diac control ddimeratest first qualitative pcrbased test myocardial damagehas nowalso hepatitis cfollowing expedited launched united states review food drug admin diagnosticsistration fdawith new cases hepatitis c reported yearthere great market need highly sensitive tests detect viral diseasewhich often asymp tomatic early stages cobas ampliprepa system fully automates multistep process preparing specimens pcr analy siswas introduced number european countries mayaddi tional market launches planned early roche entered alliances last year analysissurpassed expectations partners healthcare system demand among university decode geneticscombimatrix industrial researchers particularly quest diagnostics develop new genetics genebased diagnostics approaches molecular testing remaining strongroche con highly promising fields phar tinually expanding range tests macogenomicspredictive medicine performed using sys genomics tema recent example rapid anthrax test jointly developed within applied scienceapplied science short timeframe mayo also showed impressive growthwith clinic united states roche sales increasing local curren gives result less one ciessales industrial biochemicals hourtests dangerous supplied amounts rang pathogens currently devel ing kilograms tonnescon opedthe lightcycler comple tinue grow well ahead mar mented module fully auto ketreflecting increasing use mated nucleic acid extraction biotechnology industrial applica various sample materials tions agreement signed january rts worlds first commercial swissbased prionics gives roche cellfree protein expression system diagnostics global marketing well received market rights prionicschecka highly rts roche diagnostics sensitive test bsea new version added yet another innovative released october suitable use technology support research automated systemsenabling gene functionsan improved version simultaneous testing large numbers released december samples event massive outbreak sales lightcyclera system used amplify genetic material dna diagnostics researchers patients widest range diagnostics products market research market healthcare providers endusers research labs service laboratories patients university hospitals hospitals consumers doctors offices gps applied science molecular diagnostics centralized diagnostics near patient testing diabetes care roche diagnostics company divisions centralized diagnostics supplies market segments researchers molecular diagnostics near patient consumers knowledge gained research testingbusinesses aimed market flows directly creating improved atserving needs health professionals innovative new products segments linked together new lab network means shorter development times reduced organisation risk lower costs substantial com petitive edge new tests underscore roche raiseits operating profit margin diagnosticscustomer focuscapacity slightly better innovation ability react quickly new challenges enormous potential genomics proteomics significantly division expects dna chip tech accelerate growth entire health nology become important care sectorwith diagnostics growth driverthe first products industry likely first reap expected towards end benefits breakthroughs translated new outlookroche diagnostics con therapiesroche therefore putting tinue exploit every opportunity substantial resources strengthen inits push maintain doubledigit ing lead molecular diagnostics growth andin medium term especially pcr applicationsblood diagnosticsscreening cancer testingthe cer diagnostics market particular set undergo rapid expansion near futureroche diagnostics therefore established special unit integrated cancer care unitwith task pioneering commercially successful new tests within next two three yearsthe divisions new structure strategic realignment basis upon roche intends consolidate global lead ership diagnostics market establish leading supplier clinically actionable healthcare infor mation diagnostics protection sun important even small doses ultra violet radiation damage skin parsol slx novel uvb sunscreen roche supplies cosmetics industry use sun creams increasingly cosmetic products everyday use roche active search new dis ease prevention strategies using expertise molecular genetics roche working dis cover causes specific diseases develop innovative products early disease preventionvitamins fine chemicals division brief millions chf change sales vitamins carotenoids fine chemicals ebitda operating profit rdexpenditures employees adjusted basis vitamins fine chemicals vitamins fine chemicals division worlds leading supplier healthpromoting active ingredients feed food pharmaceuticals cosmetics industrieshoweverthe divisions performance closely linked customer industries currently experiencing slowdown markets vitamins even greater extent carotenoids subject significant pricing pressures offset increased volume sales vitamins rising sales revenues number products particularly enzymes new product entries excluding medicinal feed additives products sold may sales division increased moderately divisions operating profit margin declined per centage points consequently efforts improve profitability stepped divisions operating profit margin higher average comparable competitors major parts vitamin case resolved currently reviewing strategic alternatives business vitamins fine chemicals division consolidates leadership tough market environmentthe vitamins fine chemicals division posted sales million swiss francs compared pre vious yearsales showed growth local currencies fell swiss francsthe sales include sales ofmedicinal feed additives mfa productsup date oftheir dis posal may excluding mfa sales ofthe division increased local currencies swiss francsdespite additional pro ductivity gainson adjusted basis operating profit ebitda declined million swiss francs million swiss francsrespectivelythe divisions operating profit ebitda margins respec tivelyroughly ofthe yearon year decrease profits margins accounted onetime gain recorded sale themfa businesswhile rest attributable increases raw vitamins fine chemicals division material energy costs lower selling prices well equipped operate difficult highly competitive market thanks sales ofvitamin ebcomplex vita minsenzymesdextromethorphan new improved products cough suppressant parsol sunscreen agent showed healthy maintained market lead volume growthhoweversome prod markus altwegg head vitamins fine chemicals division ucts experienced continued price ero sionproducts launched last two years posted good growth account ofsales sales europe adversely affected bse problem outbreaks foot mouth diseasea europe wide restructuring ofmarketing oper ations enabled division reduce costs increase efficiencyin north america sales significantly vitamins fine chemicalsfrom previous yeardespite stag total divisional sales millions chf nating demand dietary supple mentsoverallsales growth latin america goodthanks strong position aquaculture robust increases vitamin premix sales feed food industries asiapacific region strong vol ume gains largely offset revenue losses due weak yenin china adjusted basis breaks ofchicken flucombined high grain prices result ofa severe droughthad negative impact sales animal nutrition segment chainegcg constituent ofgreen tea believed benefits pre division competes environ venting cardiovascular disease ment shaped increasing industrial consolidation among competing sup efforts develop new applications pliersvertical integration globali established products include collabo sation among customers effects rations academic research insti ofmounting political economic tutesone focus ofresearch role uncertainty consumer behaviour ofvitamin k reducing risk putting pressure onglobal cus osteoporosis tomerspriceswhich inturn attempt shift suppliers finallyformulation development groups using advanced technolo fuelling growth research gies new raw materials deliver developmentthe division products even stronger differen focused research development tiating benefits marketplace efforts four priorities strategic investments future new technologies imple division made mented optimise productionat substantial strategic investments new vitamin e plant sisseln switzer secure longterm cost leadership landfor exampleprocesses investments propertyplant employed improve yields equipment totalled million swiss substantially reducing byproduct waste francs air water emissions sisseln construction began rollout ofnew products theworlds largestmost advanced customer segments part ofthe divi production facility vitamin e sions growth strategyin food theplant operational late pharmaceuticals segments annual capacity focusing natural productslike tonnescomplementing egcg epigallocatechin gallate investmentcapacity expanded part ofthe human food atthe plant vitamin e intermedi vitamins fine chemicals ates lalden switzerland ensure though growth lower adequate supplies sisseln year owing economic slow facility comes stream downthedivisions objective tocontinue growing faster work completed market first part ofa multiphase project expand vitamin c facility dalry division implemented scotlandnot manufactur measures maintain profitability ing capacity increasedbut plant despite margin pressures charac also technologically upgraded terising current marketanumber reducing environmental impact ofprogrammes place achieve operations therefuture project phases additional savingsparticularly expand capacity furtherwhile purchasing production asiapacific food cosmetics pharmaceuticals sales region sales customer segment europe africa north south america animal feeds substantially decreasing manufactur one longterm goal develop ing costs deploy innovativeoptimised manu facturing processes halve pro manufacturing scheme employed duction costs ofour key vitamins biotin plant grenzach ger within next yearsroughly many modified meet sharp ofthe divisions research devel upsurge demand also opment budget used grenzacha new production facility purpose vitamin b completed startup phase became fully operational vitamins fine chemi cals division expects sales growth division opened new citric acid low singledigit rangeas plant wuxi china capable ofpro continues operate difficult ducing tonnes annuallythe economic environmentour goal longterm goal become num stabilise divisions operating ber one supplier ofthis product ebitda marginsdespite continued pricing pressuresby focusing outlooklooking long termthe profitable markets products relevant market vitamins continually improving produc fine chemicals division projected tivity show steady volume growth rate vitamins fine chemicalsin november december theeuropean commission imposed fines totalling million euros million swiss francs vita min caseadequate provisions amount already recorded group assessed adequacy ofits remaining provisions vitamin case december additional provisions million swiss francs recorded cover potential liabilities arising customer lawsuits united states amount based assump tion outstanding litigation resolved terms similar settle ments already reached individual civil suitsroche currently reviewing strategic options outside group forthe vitamins fine chemicals division vitamins fine chemicals aim integrated diagnosistherapy approach optimise treatment gene test doctors determine patients benefit treatment breast cancer drug herceptin writing pre scription goal develop integrated healthcare solutions go far beyond todays diagnostic therapeutic possibilities solu tions make possible detect predispositions earlystage disease stop progressing addition approach promises finetuned individualised treatment precise treatment monitoringactionable health information thanks strong presence pharmaceuticals diagnostics roche powerful position develop individualised diagnosis therapy solutions since first disease management projects focusing mainly viral diseases hiv hepatitis c initiated roche developed innovative programmes variety clinical conditions part ongoing efforts help meet challenges facing modern medicine integrated cancer care unit set speed development novel cancer care solutions addition crossdivisional committee established coordinate activities genetics promote knowledge transfer development promising field actionable health information helping identify predispositions diseaseifpredispositions early stage disease detectedindivid uals counselled regarding pre ventive measuressuch modifying lifestyle dietmore sensitive diagnostic techniques also making possible monitor pro gression ofcertain diseases start treatment earlierin additionbetter pretreatment selection improve therapeutic outcomes identifying patients likely benefit particular treatment medium term new technologies spawned genomics already applied genebased testing pharmacogenomic analy sis lead treatments customised patientsindividual needsintegrated healthcare solutions tailormade medicines benefit patientsthey also particularly field oncology help ensure optimum use ofthe funds available healthcare pioneering ways combine diagnostics therapeutics benefit patients first results continuing roches strategy offirmly embedding future early detection disease selec integrated healthcare concept tion best medication patient operating divisionsin roche diagnostics created integrated accurate treatment monitoring cancer care unitits task provide new diagnostic tests enable optimise therapeutic outcomes early cancer detectionassure delivery heino von prondzynski head diagnostics division oftheright drug right patient permit monitoring optimal outcomesto strengthen integrating innovation cost integrated cancer care units capa efficiencyour aim provide inte bilitiesroche diagnostics seek grated healthcare solutionsin order collaborations alliances thiswe developing innovative othercompanies academic insti diagnostic techniques extend tutions find novel diagnostic therapeutic applications ofour phar marker technology strategies maceuticals exampleby making anddevelop new clinical validation possible diagnose diseases earlier concepts actionable health informationhere ofthe results ofongo cardiocareosteocare andcancer researchdevelopment produc ing implementation ofprogrammes care roche expanding focus tion site pharmaceuticals diseases ofthe central nervous system diagnostics divisionsthe new alzheimers diseasedepression centre concentrate cancer amplicor hcv monitor test inflammatory conditions research diagnostics rdas well canbe used optimise treatment undertaking projects flowing hepatitis c pegasys combina crossdivisional programme roches vision ofintegrated healthcare tion ribavirinalargescale applied genomicsin recent years solutions clinical trial confirmed roche increasingly focused highly sensitive reliable test developing competitive advantage iscapable ofmeasuring patients areas ofgenetics genomics response therapy soon bringing together strengths startedmaking possible predict pharmaceuticals diagnostics treatment outcomes adjust divisionsaccordinglyin autumn therapy patientsindividual needs cancercare launch ofherceptin new paradigm medicine led growing demand tests detect overexpression ofher availability ofspecific diagnostic tests made possible establish standards targeted treat predisposition targeted screening prevention diagnosis therapy monitoring ment ofbreast cancer patients herceptin cardiocare diagnostic test forearly identification ofpatients riskofdeveloping heart failure ntprobnp launched set joint program applied aroutine test elecsys system genomics common coordinating test makes easier doctors framework divisionsresearch determine patients prognosis activities disciplinesthe aim also allows tomonitor treatment promote development ofa cross drugs suchas dilatrend divisional culture focused knowl torem edgesharing creating opportuni ties intensive collaborative potential synergies diag effortsgiven divisionsestab nostics therapeutics currently lished expertise type diabetes evaluated number ofareas oncologythese two areas selected including use ofneorecormon initial focus ofsupportand bondronat oncologycellcept dedicated working groups transplantation medicine set mabthera rheumatoid arthritis october roche dedicated new addition existing programmes research centre penzberg germany hivresistancehepcarecmvcare underscoring penzbergs importance actionable health information roche set high standards roche sustainability means health safety environmental operating businesses protection employees socially environmentally help ensure longterm com responsible way aim patibility activities meet needs present human health environment without compromising qual worldwide ity life future generationspeople environment modern globally active companies face social ecological challenges addition demands marketplaceas good corporate citizen roche helping find solutions company special responsibility towards employees particu larly true difficult decisions made strengthen longterm competitiveness case last year pharmaceuticals division sustainability centre environmental protection activities recognition commitment roche selected membership dow jones sustainability world indexes roche takes corporate social responsibility seriously involved wide range community programmes main focus initiatives problem hivaids developing countries people environment human resources reshaping future growth atthe endof roche group employed people worldwide less year beforeas result ofthis decrease spinoff ofgivaudan cost ofwages salariessocial security costs em ployee benefits declined million swiss francs million swiss francs decrease headcount mainly due pharmaceuticals divisions reshaping future buonas visible sign great growthinitiativelaunched spring end ofthe year total importance roche attaches employee positions cut worldwide development new training primarily nutley usawel wyn ukbasel switzerland conference centre help promote palo alto usa sitesin close cooper intensive networking communication ation employee organisations socially compatible solutions conform group worldwide ing local legal requirements practices found affected daniel villiger head corporate services employeesin allsome positions eliminated end restructuring programme human resourcesheadcount diagnostics division headcount division year end rose line divisions change change good business growth pharmaceuticals diagnostics wide range training develop vitamins fine chemicals ment opportunitiesqualifiedmoti others vated employees decisive factor roche group achieving strategic business objectivesroche offers employees headcount region year end worldclass personal professional europe development opportunitiesdesigned switzerland enhance professional north america interpersonal skillswe attach particu latin america lar importance preparing people asia forinternational leadership roles africa australia oceania complex project management tasks total group level several hundred senior managers completed two performancebased compensation part programmerun cooperation extendednow third year london business schoolwhich implementationindividualisedper designed develop leadership skills formancebased compensation asimilar programme initiated become established part ofthe pharmaceuticals division roche corporate cultureall divisions rolled outseveral continued rely thousand pharmaceuticals personnel heavily compensation models around world receive training reward individual achievement programmethe diagnos promote entrepreneurial thinking tics vitamins fine chemi thecompensation oftop executives cals divisions special depends considerable extent management development programmes individual performancetheir divisions place groups results construction ofroche forum buonas total management new senior management training personnel participated stock conference centre located option programme awarded buonas peninsula canton ofzug options roche switzerland progressing nonvoting equity securities genuss smoothlyit open schedule scheinepriced swiss francs spring centre provide eachthe underlying nonvoting executives throughout roche equity securities required pro group attractive facility com gramme bought stock prising conference seminar marketand programme thus wingdining rooms accommoda result dilution ofthe value tion beautiful setting ofroche securitiesroche subsidiaries operate additional bonus plans human resources areain focus integrity business transactionsthe aim communicate concepts ethical practice equally valid roche companies employees defineand thus preventpoten tial unacceptable practices could compromise corporate integrity stock option programmes based roche nonvoting equity securities none ofwhich results dilution value ofroche securities roche wants give managers nonmanagerial staffmore oppor tunity participate groups successfor reason cur rently considering ways ofextending performancebased executive compen sation introducing scheme would enable employees acquire roche nonvoting equity securities preferential terms behaviour businessas group operates around globeroche committed observing high ethical standards ofits business dealings company employees bound roche corporate princi ples localnational interna tional lawsfurther business integrity workshops conducted continuing programme designed explain companys ethical stan dards impart rules behaviour business enable roche employ ees perform tasks way reproachto dateover employees completed workshops human resourcessafety environmental protection sustainabilityas globally active healthcare grouproche committed putting principle ofsustainable development practice responsibly appropriatelyin sowe conscious ofthe dynamic interdepend ence ofeconomicenvironmental social factorsroche abides owncorporate healthsafety envi ronmental protection se standards guidelines ofthe international council ofchemical associations icca chemical industrys worldwide responsible care pro roches safety environmental grammein particularwe subscribe precautionary principlethe pol protection policies based luterpays principle principle ofecoefficiency principle sustainable development hans knzi head corporate safety environmental protection roche remains committed increas ing ecoefficiency reducing energy consumption associated co emissions implementing process group facility optimisationsin recognition ofits number ofincidents declined sustainability performance howeverthree employees injured roche included several green explosion company plant investment funds became amem germanythe rate ofoccupational ber ofthe dow jones sustainability accidents increased due several pro world indexes longed accidentrelated absencesbut number ofaccidents continued se expenditure amounted declinethis improved performance million swiss francsor dueinno small part uncompro ofsaleswith integrated se controls mising commitment training main investment focus development activities se officers employeesone example accidents incidentsas previ ofthis se workshop conducted ous yearsthere major incident experts throughout safety environmental protection safety environmental protection expenditure millions chf manufacturing processes reduce chemical waste continuing investment undiminishedhoweverat one operating costs ourplants scotlandfor examplea total expenditure switch aconventional chemical process one based biotechnology roche groupentitled towards eliminated anenvironmentally sustainabilitythe main topics problematic chlorinated hydrocarbon resource conservationenergy savings byproduct ofthe old process reduction ofco emissions last ten years consumption se audits performed atroche facilities ofsubstances countriesthe results confirmed deplete ozone layer high standards ofsafety reduced replacing halo environmental protection met genated hydrocarbons sub throughout groupparticular stances alternative technical solu attention paid years audits tionswe helping protect occupational health safety ozone layer reduce global warming workplace environmental stewardshiproche also saw start ofa number remains actively involved national ofinitiatives part ofthe responsible international organisations work care programmeincluding special ing improve safe management campaigns accident prevention ofchemicalssuch sgcioecd warehouse safety coordination icca ceficlast year roche contractors completed testing offour high pro duction volume chemicalspart ofits environmental protectionfurther contribution programmes designed advances energy conservation evaluate environmental impact wereachieved thanks campaigns improve knowledge throughout groupdespite slight substances used worldwide large rise production output chemical quantitiesroche experts currently manufacturingwhich particularly evaluating another five substances energy materialintensivetotal group also major contributor energy consumption group facili international chemical indus ties reduced around trys longrange research initiative increased use offuels oil aims increase understanding coal resulted higher emissions ofthe ways chemicals inter co sulfur dioxide nitrogen act human bodyanimals oxideshoweverby contrastoverall environment emissions ofvolatile organic com pounds vocs group facilities remained lowtotal chemical waste slightly result ofthe higher production outputour efforts steadily increase ecoefficiency safety environmental protectionsocial involvement social involvement long tradi tion rochewe honour respon sibilities society playing active role many different areasfrom humanitarian aid education awarenessraising campaigns health issues environmental stewardship support artsas health care companyroche make spe cial contribution fight pro mote health overcome diseasein social initiatives focused par ticularly problem ofhivaids developing countries recognise industry global fight hivaids responsibilities society go one ofthe greatest challenges posed hivaids devastation beyond developing new medications causing much ofafrica years roche cooper worlds least developed countries asany number ofstudies project ating international organisations analyses shownpeople living programmes combat problems hiv countries face major obstacles limiting access carethe caused hiv countries dissemination sharing ofknowl edge levels critical pre third world venting managing hiv infection franz b humer chairman board directors ceo anddiseasein developing countries social involvement commitment research hivaids profit sale ofmedicines hiv relentless adversary new treatments new mechanisms action hivaids countries urgently needed fight multiresistant strains virus roche already involved search antihiv medicines since group partnership principle commit made major contributions advancing treatment diagnosis hiv infec ment cooperation essential tion aids roche continues invest substantial amounts money scien making access programmes tific manpower discovering developing new antihiv medicines without developing world successthe fol patents allow us recoup enormous costs involved research could lowing two ofthe many proj continue among new drugs investigated hiv fusion inhibitors ects supported worldwide roches roche iscodeveloping trimeris currently furthest along clinical bluesky initiatives help people trials represent new approach fighting virus offering hope infected hiv indirect growing number hivinfected patients longer respond existing drugs victims ofhiv aids partnership pharmaccess internationalroche working around globe roche create ofthe basic conditions itspart fight hivaids necessary comprehensive hiv supporting numerous projects carein africawe providing con help hiv patients people trolledsustainable assistance focus whose lives indirectly affected ing building improving local pandemic medical infrastructureslaunched early pilot project aimed expanded access price dis improving treatment access countsroche founding member people hiv kenyauganda ofthe accelerating access initiative cte divoire senegalsupplies aaia collaborative project launched latest medicines hiv number ofun organisa opportunistic infectionstraining pro tionsincluding world bankthe grammes health professionals world health organization andpatient education key elements unaids united nations chil ofthis partnering initiativewhich drens fund unicefin partnership fully funded rochewith local governments industryone funding financial support ofthe main objectives ofthe initiative international communitythis ini find practical ways partici tiative could ultimately expanded pants work together closely reach far people improving access care treat ment people hiv aids thailand roche participating developing countries international collaborative pro gramme aimed specifically develop although price reductions alone ing sustainable solutions enough improve access care make real difference people living roche supplies discounted antihiv hivthe programme investi medicines countries subsaharan gating efficacy safety africa many nations desig variousantihiv treatment regimens nated un least developed thai patients local condi countrieswe feel duty tionsthanks support compa social involvementnies like rochemedicines available cost study participantswho continue receive effective antihiv treatment study completed sight life sight life nonprofit humanitarian programme founded funded roche support fight vitamin deficiency developing countries estimated million children age five risk developing condition year half million young children vitamin deficiency go blind majority die complications within year vita min important healthy vision also needed normal growthand plays key role regulating cell division building resistance infection task force sight life supported several hundred projects africa asia latin america included technical assistance projects support scientific research efforts year focused developing tech nical aids instruction materials medical paramedical training pro grammes vitamin capsules distributed millions people free charge capsules manufactured especially sight life areused primarily prevention programmes also useful treating acute vita min deficiency social involvement finance slow start roche significantly improved performance underlying operating business result strong sales growth pharmaceuticals faster expected cost savings restructuring programme reshaping future growththus programme achieved payback within one yearthe operating profit margin underlying pharmaceuticals business improved percentage points close targeted range diagnostics continued grow doubledigit rates improved profitability furtherfor treasury operations difficult yearthe decline world stock markets led reduced financial resultonce roche produced strong positive cash flow operating activities remains solidly financed financefinancial review highlights millions chf figures reported figures reported financial statements adjusted basis change change sales ebitda operating profit net income roche achieved reported net income billion swiss francs decrease previous year decrease almost entirely due special items million swiss francs pharmaceuticals division restructuring costs million swiss francs expenses vitamin case nonrecurrence billion swiss franc pretax gain sale genentech shares underlying operating results show continued improvement increased sales pharmaceuticals diagnostics improved ongoing cost struc ture operating profit adjusted basis excludes effects special items increased billion swiss francs adjusted net income billion swiss francs improved operating performance offset reduced financial result increased tax expenses improve transparency groups results financial statements include additional disclosures breakdown pharmaceuticals division roche prescription genentech prescription otc detailed split financial income cash flows operating activities billion swiss francs million swiss francs used financing activities reduce debt billion swiss francs reinvested marketable securities net liquidity increased million swiss francs billion swiss francs liquid funds ongoing cash flow generation support strengthening roche unique healthcare company two hightech pillars erich hunziker chief financial officer financial review income statement millions chf figures reported figures reported financial statements adjusted basis change change sales cost sales gross profit marketing distribution research development administration amortisation intangible assets impairment longterm assets pharmaceuticals division restructuring impairment longterm assets restructuring costs operating income expense net gain sales genentech shares vitamin case operating profit financial income expense net profit taxes income taxes profit taxes changes accounting policies income applicable minority interests share result associated companies net income diluted earnings per share nonvoting equity security chf adjusted figures used internal management roche group represent results groups underlying ongoing operations exclude special items include continuing businesses see pages full description reconciliation financial reviewresults reported consolidated financial statementsin millions chf operating profit decrease due impact special items operating profit decreased billion swiss francs operating result includes six months results fragrances flavours division addition net operating income billion swiss francs arising special items notably billion swiss franc gain sale genentech shares billion swiss franc impairment charge arising change accounting policy see table operating profit includes net operating expenses billion pharmaceuticals division restructuring vitamin case excluding items operating profit increased billion swiss francs isdiscussed commentary adjusted results pharmaceuticals division restructuring nonrecurring costs million swiss francs incurred due implementation pharmaceuticals divisions reshaping future growth programme previously indicated total restructuring costs estimated atapproximately billion swiss francs approximately noncash impairment charges programme already led significant improvements cost structure asdescribed vitamin case based development litigation recent settlement negotiations mainly united states group recorded additional provisions million swiss francs amount reflects terms settlements achieved recently number individual civil cases litigation process new litigation may arise possible final obligation may different net income decrease due impact special items factors cause decrease operating profit lead large decrease net income addition financial income includes gains million swiss francs arising part disposal associated company income taxes includes tax effects various special items also onetime gain arising changes accounting policies excluding items net income decreased billion swiss francs discussed commentary adjusted results results adjusted basisin millions chf sales increased sales doubledigit growth diagnostics excluding fragrances flavours division spun mid adjusted salesincreased pharmaceuticals sales grew particularly good performance new products mabtherarituxan herceptin xeloda robust sales longerestablished products cellcept kytril acquired end contributed sales offset impacts patent expiry verseddormicum delisting draganon japan diagnostics showed strong doubledigit sales growth driven molecular diagnostics diabetes care relative fall sales vitamins finechemicals due inclusion medicinal feed additives mfa products sold may comparative figure excluding mfa sales increased due increased volume financial review sales change change local chf currencies pharmaceuticals diagnostics vitamins fine chemicalsa b sales adjusted basis fragrances flavours reclassificationa total sales vitamins fine chemicals division sales adjusted include reclassification million swiss francs sales fragrances flavours division first half prior spinoff b vitamins fine chemicals division sales include sales medicinal feed additives mfa products date disposal may excluding mfa vitamins fine chemicals sales increased local currencies chf operating profit increase ongoing operations operating profit increased billion swiss francs adjusted basis excludes fragrances flavours special items see table increase primarily driven sales growth significantly improved cost structure result reshaping future growth initiative operating profit percentage sales improved percentage points result achieved spite result including million swiss francs gains continuing product portfolio asset realignments respect sale north american rights coreg mfa products reoccur gross profit increase billion swiss francs gross profit margin improved percentage points reflects particularly strong growth highmargin pharma ceuticals products diagnostics business areas productivity improvements divisions andthe effects pharmaceuticals divisions reshaping future growth initiative improvement achieved spite continued pressure prices particular vitamins fine chemicals new generation products diagnostics increased production service costs marketing distribution decrease billion swiss francs full year rise first half year due beneficial effects reshaping future growth initiative allowing focused spend growth areas whilst increasing sup port key growth drivers supporting new product launches pharmaceuticals diagnostics marketing distribution percentage sales fell percentage points research development decrease billion swiss francs growth research development expenses genentech diagnostics support strong research devel opment pipeline new strategic alliances collaborations inlicensing agreements offset reduced expenditure roche prescription reflects even intensive review development portfolio impacts reshaping future growth initiative research development costs percentage sales group level declined pharmaceuticals accounts groups research development expenses theydecreased administration increase billion swiss francs well sales growth result continuous efficiency improvements impacts reshaping future growth initiative financial reviewamortisation intangible assets amortisation expenses increased due additional amortisation following acquisition kytril december roches amortisation charge currently sales continues significantly higher industry average primarily due goodwill arising growth acquisitions accounting treatment acquisitions international accounting standards impairment longterm assets excluding impairment entries recorded arising implementation reshaping future growth programme significant impairment entries operating income expense net swing approximately billion swiss francs income million swiss francs expense million swiss francs major factors increased net royalty expenses particular diagnostics exchange losses receivables due devaluation turkish brazilian argentine currencies addition figures include approximately million swiss francs gains ongoing realignments product portfolio financial income anticipated net financial income billion swiss francs similar level halfyear decline world markets negative impact groups financial income period despite group generated sufficient financial income cover groups financial expenses consist mainly interest costs net income equity investments billion swiss francs includes billion swiss franc gain sale labcorp shares june decline compared reflecting difficult market conditions interest expense billion swiss francs broadly level previous year interest expense particularly amortisation debt discount tends less volatile elements net financial income order increase transparency groups financial result information composition net financial income note consolidated financial statements expanded income taxes increase effective tax rate operating income makes considerably higher proportion pretax income case previous years leads increase groups effective tax rate operating income typically occurs jurisdictions higher tax rates compared finan cial income furthermore financial income includes gain sale labcorp shares taxable united states consequently although adjusted pretax income higher tax charge higher associated companies minority interests currently significant impact group results expense minority interest continues increase overall contribution genentech net income increases income associated companies consists mainly income labcorp period prior june time accounted associated company remaining associated companies relatively minor effect net income decrease adjusted basis net income lower billion swiss francs increase operating profit offset slightly lower financial income proportionately higher tax charge financial review divisional results adjusted basis millions chf divisional ebitda operating sales operating profit third parties ebitda sales profit sales pharmaceuticals total prescription roche prescription genentech prescription otc diagnostics vitamins fine chemicals group total pharmaceuticals total prescription roche prescription genentech prescription otc diagnostics vitamins fine chemicals group total adjusted figures used internal management roche group represent results groups underlying ongoing operations exclude special items include continuing businesses seepages full description reconciliation ebitda earnings interest financial income tax depreciation amortisation including impairment corresponds operating profit depreciation amortisation including impairment pharmaceuticals improved margins pharmaceuticals sales local currencies increased particularly strong sales oncology products cellcept pharmaceuticals operating profit grew billion swiss francs due higher sales well considerably improved cost structure result reshaping future growth initiative ebitda pharmaceuticals division also increased operating profit margin improved percentage points ebitda margin percentage points reshaping future growth initiative progressing faster expected cost savings estimated order million swiss francs full effect measures annual cost savings approximately million swiss francs realised restructuring costs million swiss francs recognised financial statements comprise employee costs million swiss francs impairment charges related closure certain operations million swiss francs costs total restruc turing costs estimated approximately billion swiss francs approximately noncash impairment charges enhance comparability restructuring costs excluded adjusted results financial reviewtotal prescription prescription drug sales roche genentech increased local currencies swiss francs billion swiss francs operating profit higher operating margin improved sales roche prescription sales rose local currencies swiss francs operating profit higher main positive factors higher sales favourable impacts reshaping future growth initiative considerably improved cost structure offset additional amortisation following acquisition kytril million swiss francs gain sale north american rights coreg comparative genentech prescription sales improved billion swiss francs growth swiss francs well asin local currencies operating profit reached million swiss francs equivalent sales turnaround operating loss due strongsales growth spite higher costs support growth genentechs oper ating result includes million swiss francs amortisation mainly arising acquisition accounting ebitda totalled million swiss francs sales slightly ahead level otc sales rose local currencies sales swiss francs showing slight decline billion swiss francs modest sales growth ahead market growth oper ating profit margin amounted achieved aggressive focus cost control spite substantially increased foreign exchange losses receivables diagnostics another strong result sales development diagnostics division significantly outperformed market overall growth rate local currencies division market leader diagnostics allfive business areas division applied science molecular diagnostics centralized diagnostics near patient testing diabetes care grew faster market due strong sales growth roche diagnostics achieved doubledigit increase operating profit million swiss francs ebitda also grew doubledigit rate million swiss francs operating profit margin increased percentage points ebitda margin percentage points vitamins fine chemicals ongoing price pressure sales vitamins fine chemicals division stable local currencies excluding medicinal feed additives mfa products sold may sales increased local curren cies vitamins fine chemicals operating profit ebitda dropped approximately million swiss francs million swiss francs respectively approximately decrease due inclusion figures onetime gain sale mfa products remaining due increased raw material energy prices somewhat lower selling prices result consists costs corporate headquarters financial review balance sheet millions chf change longterm assets current assets total assets equity minority interests noncurrent liabilities current liabilities total equity minority interests liabilities foreign currency translation effects movements balance sheet positions due combination factors movements foreign currency exchange rates effect balance sheet positions assets liabilities group companies report foreign currencies notably us dollar euro translated swiss francs yearend rate effects expected likely continue increase especially alliance chugai result increasing part groups balance sheet japanese yen base currency marketable securities derivatives booked fair value following implementation new international accounting standard major change accounting policy relates treatment financial instruments two signifi cant impacts group firstly derivatives reported balance sheet fair value gains losses included financial income secondly availableforsale mar ketable securities investments recorded market value changes market value recorded equity realised point included financial income due falls world stock markets unrealised net losses net tax minority interests billion swiss francs recorded equity december given overall level groups marketable securities investments billion swiss francs represents net unrealised losses approximately end year compared net unrealised gains beginning year provisions litigation november december european union announced fines totalling million euros million swiss francs respect vitamin case adequate provision amounts already recorded amounts paid discussed group recorded provisions million swiss francs respect vitamin case addition provisions ongoing litigation notably igen discussed note consolidated financial statements amounts recorded managements best estimate based currently available information litigation process new liti gation may arise possible final obligation may different total amount provisions isnot disclosed may prejudice groups position current litigation offbalance sheet financing group offbalance sheet financing groups subsidiary genentech entered synthetic lease structure certain facilities discussed note consolidated financial statements reported onbalance sheet increase property plant equipment billion swiss francs corresponding increase short term longterm debt groups operating results include full years depreciation charge facilities financial reviewreinvestment positive cash flows cash generated operations reinvested groups marketable securities port folio causing billion swiss francs increase current assets cash flows net liquidity millions chf cash flow statement operating activities income taxes income taxes paid activities operating activities financing activities investing activities net effect currency translation cash increase decrease cash group continued show strong cash generation pretax cash generated operations billion swiss francs mainly driven strong ebitda financing side significant cash flows billion swiss francs proceeds lyons v bond issue july billion swiss franc repayment maturity bull spread bonds may also general reduction longterm bank borrowing group paid billion swiss francs dividends april significant investing cash flow billion swiss franc proceeds sale labcorp shares june capital expenditure continued previous levels major acquisitions divestments funds immediately required reinvested groups marketable securities portfolio full cash flow state ment given note consolidated financial statements net liquidity december january cash marketable securities investments derivative financial instruments net equity instruments financial assets longterm debt shortterm debt total debt net liquidity group revised definition net liquidity following recent changes accounting policies net liquidity defined financial assets market value less debt liabilities increased year million swiss francs billion swiss francs due thereinvestment cash generated partly offset fall global stock prices affecting market values marketable securities equity instruments billion swiss francs debt due genentech synthetic leases included balances financial review subsequent events majority holding chugai december roche chugai announced enter alliance create leading researchdriven japanese pharmaceutical company alliance subject approval chugais shareholders appropriate regulatory authorities willsee merger chugai roches japanese pharmaceuticals subsidiary nippon roche alliance expected completed late roche majority shareholder interest purely accounting terms chugai accounted fully consolidated subsidiary roche group minority interest similar way genentech currently reported within roche significant effects acquisition accounting including ongoing impacts amortisation goodwill intangible assets fair value adjustments vitamins fine chemicals division group reassessing strategic options development vitamins fine chemicals division discussed note consolidated financial statements theannouncement detailed formal plan group continue account divisionaspart continuing operations sale labcorp shares february labcorp filed registration statement announcing group plans offer sale million shares labcorp option sell million shares cover overallotments assuming total million shares would sold roches ownership interest labcorp would reduced approximately approxi mately amortisation goodwill following implementation recent changes companies using united states generally accepted accounting principles us gaap longer required amortise goodwill instead must carry regular impairment review roche continue amortise goodwill asrequired international accounting standards ias expected charge approximately million swiss francs financial reviewforeign exchange rates exchange rates swiss franc december average december average december usd eur gbp jpy chfusd exchange rate j f j j n financial review adjusted basis concept adjusted basis managements view groups ongoing operations presented consistent comparable basis consolidated results roche group significantly influenced various special items also changes international accounting standards years improve visibil ity underlying business adjusted results also presented adjusted results used internal management business represent results groups underlying ongoing operations principles used compile adjusted results applied consistent basis major concepts follows adjusted results include gains losses continuing product portfolio asset realignments sales income newly acquired products impacts sales income patent expiry withdrawal disposal existing products impairments longterm assets part major restructuring costs normal ongoing restructuring gains losses sales marketable securities adjusted results exclude discontinuing operations sale spinoff whole business onetime costs major restructuring fundamental reorganisations charges exceptional legal cases gains losses arising disposal fully consolidated subsidiaries associated companies transition effects changes accounting policies specific items excluded adjusted results adjusted results exclude nonrecurring costs pharmaceuticals division restructuring additional charges respect vitamin case adjusted results exclude results fragrances flavours division prior givaudan spinoff june gain sale genentech shares gain sale labcorp shares october impact fair value adjustment genentech inventories arising acquisition transition effects new impairment policy credit changes accounting policies financial reviewreconciliation reported figures adjusted basisin millions chf reference numbers indicate corresponding notes consolidated financial statements sales operating year ended december third parties ebitda profit net income reported financial statements major restructuring nonrecurring costs reshaping future growth initiative legal cases additional charges respect vitamin case income taxes results adjusted basis sales operating year ended december third parties ebitda profit net income reported financial statements discontinuing operations results fragrances flavours division prior givaudan spinoff reclassification intercompany sales fragrances flavours division sales third parties gains losses fully consolidated subsidiaries associated companies gain reduction ownership genentech gain reduction ownership labcorp impact fair value adjustment genentech inventories transition effects changes accounting policies impairment longterm assets business combinations intangible assets income taxes income applicable minority interests results adjusted basis financial review consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements consolidated income statement millions chf year ended december sales cost sales gross profit marketing distribution research development administration amortisation intangible assets impairment longterm assets pharmaceuticals division restructuring impairment longterm assets restructuring costs operating income expense net gain sales genentech shares vitamin case operating profit financial income expense net profit taxes income taxes profit taxes changes accounting policies income applicable minority interests share result associated companies net income basic earnings per share nonvoting equity security chf diluted earnings per share nonvoting equity security chf figures include results fragrances flavours division givaudan spinoff june see note number shares per share information restated share split took place may seenote consolidated financial statementsconsolidated balance sheet millions chf december longterm assets property plant equipment intangible assets investments associated companies investments deferred income tax assets longterm assets total longterm assets current assets inventories accounts receivable trade current income tax assets current assets marketable securities cash cash equivalents total current assets total assets equity share capital nonvoting equity securities genussscheine pm pm equity instruments retained earnings total equity minority interests noncurrent liabilities longterm debt deferred income tax liabilities liabilities postemployment benefits provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable trade accrued current liabilities total current liabilities total equity minority interests liabilities pm pro memoria nonvoting equity securities nominal value see note consolidated financial statements consolidated statement changes equity millions chf year ended december share capital balance january december nonvoting equity securities genussscheine balance january december pm pm equity instruments balance january previously reported changes accounting policies balance january restated movements year balance december retained earnings balance january changes accounting policies balance january restated net income dividends paid givaudan spinoff special dividend transfer net assets changes fair value reserves net equity component new convertible debt currency translation gains losses balance december total equity december pm pro memoria nonvoting equity securities nominal value see note consolidated financial statementsconsolidated cash flow statement millions chf year ended december cash flows operating activities cash generated operations increase decrease working capital costs vitamin case paid costs pharmaceuticals division restructuring paid costs genentech legal settlements paid restructuring costs paid payments made defined benefit postemployment plans operating cash flows cash flows operating activities income taxes paid income taxes paid total cash flows operating activities cash flows financing activities proceeds issue longterm debt repayment longterm debt transactions equity instruments increase decrease shortterm borrowings interest dividends paid givaudan spinoff special dividend givaudan cash balances financing cash flows total cash flows used financing activities cash provided operating financing activities cash flows investing activities purchase property plant equipment intangible assets disposal property plant equipment intangible assets acquisition subsidiaries associated companies products divestments subsidiaries associated companies products interest dividends received purchases marketable securities net sales total cash flows used investing activities net effect currency translation cash increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year figures include cash flows fragrances flavours division givaudan spinoff june see note consolidated financial statements notes consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements summary significant accounting policies basis preparation consolidated financial statements consolidated financial statements roche group prepared accordance international accounting standards prepared using historical cost convention except disclosed accounting policies certain items including derivatives availableforsale investments shown fair value approved forissue board directors february preparation consolidated financial statements requires management make estimates assumptions affect reported amounts revenues expenses assets liabilities disclosure contingent liabilities date financial statements future estimates assumptions based managements best judgement date financial statements deviate actual circumstances original estimates assumptions modified appropriate year circumstances change consolidation policy financial statements consolidated financial statements roche holding ltd acompany registered switzerland subsidiaries hereafter group subsidiaries companies controlled directly indirectly roche holding ltd control defined power govern financial operating policies enter prise obtain benefits activities control normally evidenced roche holding ltd owns either directly indirectly voting rights companys share capital companies acquired year consolidated date oper ating control transferred group subsidiaries divested included date divestment companies acquired resold consolidated classified assets held sale carried fair value assets identified divestment following year reclassified assets held sale within current assets assets normally consist mainly inventories property plant equipment longterm assets investments associated companies accounted equity method compa nies group exercises significant influence control normally evidenced group owns voting rights company inter ests joint ventures reported using linebyline proportionate consolidation method foreign currency translation group companies maintain financial records local currency certain group companies maintain financial information group reporting purposes us dollars swiss francs euros measurement currencies companies concerned local transactions currencies initially reported using exchange rate date transaction gains losses settlement transactions well gains losses monetary assets liabilities denominated currencies included income except deferred equity qualifying cash flow hedges notes consolidated financial statementsupon consolidation assets liabilities group companies using measurement currencies swiss francs foreign entities translated swiss francs using yearend rates exchange sales costs expenses net income cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly equity divestment foreign entity identified cumulative currency translation differences relating foreign entity recognised income part gain loss divestment revenues cost sales sales represent amounts received receivable goods supplied services rendered customers deducting volume discounts sales taxes revenues sale products recognised upon transfer customer significant risks rewards usually upon shipment royalty income recognised accrual basis accordance economic substance ofthe agreement receipts upfront milestone payments similar nonrefundable payments relating sale licensing products technology initially reported deferred income recognised income period development collaboration manufacturing obligation revenues recorded earned services performed cost sales includes corresponding direct production costs related produc tion overhead goods manufactured services rendered research development research costs charged income incurred exception buildings major items equipment capitalised depreciated development costs milestone payments similar nonrefundable upfront product licence payments capitalised intangible assets probable future economic benefits flow group amortised straightline basis period expected benefit reviewed impairment balance sheet date development costs charged income incurred since criteria recognition asset met employee benefits wages salaries social security contributions paid annual leave sick leave bonuses nonmonetary benefits accrued year associated services rendered employees group group provides longterm employee benefits cost accrued match rendering services employees concerned group operates number defined benefit defined contribution plans throughout world cost year defined benefit plans determined using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth longterm expected rates return plan assets discount rates based market yields highquality corporate bonds country concerned differences assumptions actual experiences effects changes actuarial assumptions allocated estimated average remaining working lives employees differences exceed defined corridor past service costs allocated average period benefits become vested pension assets liabilities different defined benefit schemes offset unless group legally enforceable right use surplus one plan settle obligations plan pension assets recognised extent group able derive future economic benefits way refunds plan reductions future contributions groups contributions defined contribution plans charged income statement year relate notes consolidated financial statements taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based onincome property capital taxes included within operating expenses financial expenses according nature provision income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries made current inten tion remit earnings deferred income taxes provided using liability method deferred income taxes recognised temporary differences tax bases assets liabilities carrying values financial reporting purposes deferred income tax assets relating carryforward unused tax losses recognised extent probable future tax able profit available unused tax losses utilised current deferred income tax assets liabilities offset income taxes levied taxation authority legally enforceable right offset property plant equipment property plant equipment initially recorded cost purchase construction depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows buildings land improvements years machinery equipment years office equipment years motor vehicles years investment grants similar assistance projects initially recorded deferred income inother noncurrent liabilities subsequently recognised income useful lives related assets repairs maintenance costs recognised expenses incurred borrowing costs capitalised assets acquired finance leases depreciated estimated useful lives payments made operating leases charged income straightline basis period lease intangible assets business combinations goodwill recorded intangible asset surplus cost acquisition fair value identifiable assets acquired goodwill fair value adjustments treated asassets liabilities acquired company recorded local currency company patents licences trademarks intangible assets initially recorded fair value assets acquired business combination fair value allocated acquisition accounting acquired business combination initial fair value cost notes consolidated financial statementsall intangible assets amortised useful lives straightline basis estimated useful lives major classes intangible assets follows goodwill years patents licences trademarks lower legal duration intangible assets economic useful life maximum years impairment longterm assets recoverable amount asset higher net selling price value inuse less carrying amount carrying amount reduced recoverable value reduction reported income statement impairment loss value use calculated using estimated cash flows generally fiveyear period extrapolating pro jections subsequent years discounted using appropriate longterm pretax interest rate impairment arises useful life asset question reviewed ifnecessary future depreciationamortisation charge accelerated inventories inventories stated lower cost net realisable value cost determined first firstout method cash cash equivalents cash cash equivalents comprises cash hand time call current balances banks similar institutions readily convertible known amounts cash subject insignificant risk changes value definition also used cash flow statement equity instruments groups holdings equity instruments recorded deduction equity theoriginal cost acquisition consideration received subsequent resale equity instruments movements reported changes equity instruments acquired primarily meet obligations may arise respect certain groups debt instruments debt instruments debt instruments initially reported cost proceeds received net transaction costs subsequently reported amortised cost using effective interest method tothe extent debt instruments hedged qualifying fair value hedges hedged element recorded fair value discount net proceeds received principal value due redemption amortised duration debt instrument isrecognised part interest expense income statement issue convertible debt instruments cost liability portion initially calculated using market interest rate equivalent nonconvertible instrument remainder net proceeds allocated equity conversion option reported equity deferred income taxes liabilities liability element subsequently reported amortised cost amortisation debt discount release deferred tax liabilities recognised income statement duration debt instrument value equity conversion option changed future periods limited conversion preferred stock substance financial liability rather equity instrument therefore classified longterm debt balance sheet related dividend payments treated interest expense notes consolidated financial statements provisions provisions recognised legal constructive obligation incurred probably lead outflow resources reasonably estimated provisions recorded estimated ultimate liability expected arise taking account foreign currency effects time value money contingent liability recorded existence obligation confirmed future events amount obligation measured reasonable reliability fair values fair value amount financial asset liability instrument could exchanged knowledgeable willing parties arms length transaction determined reference quoted market prices adjusted estimated transaction costs would incurred actual transaction use established estimation techniques option pricing models estimated discounted values cash flows fair values balance sheet date approximately line reported carrying values unless specifi cally mentioned notes consolidated financial statements international accounting standards several revised new standards issued international accounting standards committee interpretations standing interpretations committee became effective january principal item affecting group standard financial instruments recogni tion measurement effects described accounting effects new standard implemented effective january accord ance transition arrangements standard comparative financial statements restated effects implementation opening balances shown table net assetsin millions chf investments marketable securities derivative financial instruments deferred income taxes minority interests total increase net assets equityin millions chf retained earnings total increase equity necessary balance sheet comparatives reclassified extended previously reported results take account presentational changes changes made previously reported income statement comparatives notes consolidated financial statementsfinancial assets financial assets principally investments including marketable securities classified either heldfortrading availableforsale heldtomaturity originated group heldfortrading investments acquired principally generate profit shortterm fluctuations price heldtomaturity investments securities fixed maturity group intent ability hold maturity investments originated group loans longterm financial assets created group acquired issuer inaprimary market investments considered availableforsale investments initially recorded cost including transaction costs purchases sales recognised settlement date heldfortrading investments subsequently carried atfair value changes fair value recorded financial income expense period arise heldtomaturity investments subsequently carried amortised cost using effective interest rate method availableforsale investments subsequently carried fair value changes fair value recorded equity availableforsale investments sold impaired otherwise disposed cumulative gains losses previously recog nised equity included financial income expense current period groups previous accounting policies longterm investments carried cost less permanent diminution value marketable securities valued lower cost market value derivatives derivative financial instruments initially recorded cost including trans action costs derivatives subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments see changes fair value recorded financial income expense period arise groups previous accounting policies gains losses derivative financial instru ments used hedge potential exchange rate exposures deferred offset losses gains specific transactions hedged fee agreed establishing contract amortised duration contract gains losses derivative finan cial instruments used hedge potential interest rate exposures recognised adjustments interest expense gains losses derivative financial instruments used trading pur poses taken income arose hedging purposes hedge accounting hedging relationships may three types fair value hedges hedges particular risks may change fair value recognised asset liability cash flow hedges hedges particular risks may change amount timing future cash flows hedges net investment foreign entity hedges particular risks may change carrying value net assets foreign entity qualify hedge accounting hedging relationship must meet several strict conditions ondocumentation probability occurrence hedge effectiveness reliability measurement conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship particular derivatives reported fair value changes fair value included financial income expense notes consolidated financial statements qualifying fair value hedges hedging instrument recorded fair value hedged item recorded previous carrying value adjusted changes fair value attributable hedged risk changes fair values reported financial income expense qualifying cash flow hedges hedging instrument recorded fair value portion change fair value effective hedge included equity remaining inef fective portion reported financial income expense hedging relationship hedge firm commitment highly probable forecasted transaction cumulative changes fair value hedging instrument recorded equity included initial car rying value asset liability time recognised qualifying cash flow hedges cumulative changes fair value hedging instrument recorded equity included financial income expense time forecasted transaction affects net income qualifying hedges net investment foreign entity hedging instrument recorded fair value portion change fair value effective hedge included equity remaining ineffective portion recorded financial income expense hedging instrument derivative equity cases entity disposed cumu lative changes fair value hedging instrument recorded equity included financial income expense time disposal changes effective january several revised new standards interpretations became effective january themost significant follows impairment assets effective january group recognised impairment charges million swiss francs relating acquired intangible assets reduction deferred tax liabil ities million swiss francs also recorded giving net charge million swiss francs consolidated results intangible assets business combinations effective january group recorded certain reclassifications adjustments original purchase accounting allo cations reflect revised balances resulted credit income net tax minority interests million swiss francs changes fully described consolidated financial statements notes consolidated financial statements financial risk management financial risk management within group governed policies guidelines approved senior management policies guidelines cover foreign exchange risk interest rate risk market risk credit risk liquidity risk group policies guidelines also cover areas cash management investment excess funds raising short longterm debt group companies report details financial instruments outstanding financial liquidity togroup treasury least monthly basis new post financial risk manager created oversee compliance groups financial risk management policies guidelines group accordance risk management guidelines continues monitor risks deemed appropriate certain risks significantly altered use financial instruments derivatives group management believes order create optimum value group desirable eliminate mitigate possible market fluctuations addition group management wide discretion undertake various contracts could result significant trading positions change value market prices change foreign exchange risk group operates across world exposed movements foreign currencies affect ingits net income financial position expressed swiss francs group continues tomonitor currency exposures appropriate enters transactions aim ofpreserving value assets commitments anticipated transactions group uses forward contracts foreign currency options optimise certain anticipated foreign exchange revenues cash flows financing transactions transaction exposure arises amount local currency paid received trans actions denominated foreign currencies may vary due changes exchange rates many group companies income primarily local currency significant amount expen diture especially purchase goods resale interest repayment loans foreign currencies similarly transaction exposure arises net balances monetary assets held foreign currencies group companies manage exposure local level necessary means financial instruments options forward contracts addition group treasury monitors total worldwide exposure help comprehensive data received amonthly basis translation exposure arises consolidation foreign currency denominated finan cial statements groups foreign subsidiaries effect groups consolidated equity shown currency translation movement group hedges significant net investments foreign currencies taking foreign currency loans issuing foreign currency denominated debt instruments major translation exposures monitored regular basis significant part groups cash outflows research development production admin istration denominated swiss francs much smaller proportion groups cash inflows swiss franc denominated result increase value swiss franc rela tive currencies adverse impact consolidated net income similarly relative fall value swiss franc favourable effect results published swiss francs notes consolidated financial statements interest rate risk interest rate risk arises movements interest rates could adverse effects groups net income financial position changes interest rates cause variations interest income expenses interestbearing assets liabilities addition affect market value certain financial assets liabilities instruments described following section market risk interest rates groups major debt instruments fixed described note reduces groups exposure changes interest rates group companies manage shortterm interest rate risk local level necessary using financial instruments interest rate forward contracts swaps options market risk changes market value certain financial assets liabilities instruments affect net income financial position group longterm investments held strategic pur poses marketable securities held fund management purposes risk loss value reduced reviews prior investing concentration investments continuous monitoring performance investments changes risk configuration investments equity fixed income instruments entered basis approved guidelines regard liquidity credit rating credit risk credit risk arises possibility counterparty transaction may unable unwilling meet obligations causing financial loss group trade receivables subject policy active risk management focussing assessment country risk credit availability ongoing credit evaluation account monitoring procedures significant concentrations within trade receivables counterparty credit risk due groups large number customers wide geographical spread country risk limits exposures continuously monitored exposure financial assets credit risk controlled setting policy limiting credit exposure highquality counterparties ongoing reviews credit ratings limiting individual aggregate credit exposure accordingly liquidity risk group companies need sufficient availability cash meet obligations individual companies responsible cash management including shortterm investment cash surpluses raising loans cover cash deficits subject guidance group certain cases approval group level group maintains sufficient reserves cash readily realisable marketable securities meet liquidity requirements times addition strong international creditworthiness group allows make efficient use international capital markets financing pur poses notes consolidated financial statements group organisation overview operating subsidiaries associated companies included pages addition operating companies group holding finance companies chugai december roche chugai announced enter alliance create leading researchdriven japanese pharmaceutical company alliance see merger chugai groups japanese pharma subsidiary nippon roche transaction accounted using purchase method accounting newly merged company known chugai become fully consolidated subsidiary roche group minority interest new company listed tokyo stock exchange thetransaction subject approval chugais shareholders appropriate regulatory authorities expected completed late group announced public tender offer chugais outstanding share capital terms alliance group may also subscribe additional new shares newly merged company groups ownership amira november group acquired share capital amira medical inc amira amira company active diabetes monitoring based united states net consideration paid million swiss francs allocated follows net assets acquiredin millions chf goodwill intangible assets deferred income taxes provisions net assets liabilities total following acquisition restructuring programme announced resulted restructuring charges million swiss francs recorded part operating income expense net see note restructuring programme substantially complete june transactions march group sold million shares genentech public offering yielding proceeds million us dollars million swiss francs resulting pretax gain incidental costs million swiss francs december group acquired global rights kytril million swiss francs december group sold exclusive rights coreg united states canada million swiss francs gain sale million swiss francs notes consolidated financial statements segment information millions chf divisional information roche genentech total prescription prescription otc pharmaceuticals segment revenues segment revenuedivisional sales less interdivisional sales divisional sales third parties segment resultsoperating profit segment assets liabilities divisional assets segment assets segment assets nonsegment assets total assets divisional liabilities segment liabilities segment liabilities nonsegment liabilities total liabilities segment information capital expenditure depreciation amortisation impairment longterm assets research development costs share result associated companies investments associated companies number employees group three divisions pharmaceuticals diagnostics vitamins fine chemicals fragrances flavours division spunoff see note disclosure pharmaceuticals division expanded include three reportable segments roche prescription genentech prescription otc segment others consists costs corporate headquarters reasonably attributed reported segments transfer prices interdivisional sales set onan arms length basis divisional assets consist primarily property plant equipment goodwill intangible assets receivables inventories divisional liabili ties consist trade accounts payable segment assets liabilities consist assets liabilities reasonably attributed reported business segments include pension assets liabilities provisions nonsegment assets liabilities mainly include current deferred income tax balances financial assets liabilities principally cash marketable securities investments associated companies investments debt notes consolidated financial statementsvitamins continuing fragrances diagnostics fine chemicals others operations flavours group capital expenditure comprises additions intangible assets including goodwill additions property plant equipment including arising acquisitions roche prescription segment result includes million swiss francs expenses respect pharmaceuticals division restruc turing includes million swiss francs impairment expense see note vitamins fine chemicals result includes million swiss francs expenses additional charges respect vitamin case see note roche prescription segment result includes million swiss francs impairment expenses following implementation new international accounting standard see note genentech prescription segment result includes million swiss francs gain sale genentech shares million swiss francs expense respect fair value adjustments inventories following acquisition genentechs share capital notes consolidated financial statements geographical information sales third parties destination segment assets capital expenditure switzerland european union rest europe europe north america latin america asia africa australia oceania segment total nonsegment assets consolidated total switzerland european union rest europe europe north america latin america asia africa australia oceania segment total nonsegment assets consolidated total segment assets include property plant equipment goodwill intangible assets receivables inventories andother assets reasonably attributed reported business segments nonsegment assets mainly include current deferred income tax balances financial assets principally cash marketable securities investments associated companies investments capital expenditure comprises additions intangible assets including goodwill additions property plant equipment including arising acquisitions notes consolidated financial statements vitamin case following settlement agreement us department justice may regarding pricing practices vitamin market overall settlement agreement class action suitbrought us buyers bulk vitamins group recorded provisions respect vitamin case provisions groups best estimate time total liability may arise taking account currency movements time value money provisions legal fees recorded separately november december european union announced fines totalling million euros million swiss francs respect vitamin case appropriate provision amounts already recorded december group reassessed adequacy remaining provisions vitamin case based development litigation recent settlement negotiations mainly inthe united states direct customers previously opted settlement group recorded additional provisions million swiss francs amount reflects terms settlements achieved recently number individual civil cases total amount provisions liability group expects pay adjusted foreign currency translation effects time value money assessment based currently available information litigation process new litigation may arise possible final obligation may different total amount provisions disclosed may prejudice groups position current litigation net cash outflows million swiss francs net cash inflow million swiss francs pharmaceuticals division restructuring may group announced reshaping future growth initiative major restruc turing pharmaceuticals division objective improving longterm profitability division increasing sales improving divisions cost structure group announced approximately job reductions following two three years conjunc tion closure reorganisation certain facilities principally us uk switzer land restructuring costs million swiss francs charged consist employee costs million swiss francs impairment charges million swiss francs related closure certain operations closure costs million swiss francs netof gain curtailment postemployment defined benefit plans million swiss francs see note employee closure costs million swiss francs paid december andthe remaining million swiss francs included liabilities balance sheet december givaudan spinoff millions chf june groups fragrances flavours division spun independent company name givaudan shares givaudan distributed date special dividend holders roche shares nonvoting equity securities result spinoff assets totalling billion swiss francs liabilities totalling billion swiss francs transferred givaudan notes consolidated financial statements results cash flows fragrances flavours division spinoff june included consolidated figures however consolidated balance sheet shown spinoff include divisions assets liabilities sales results assets liabilities net cash flows fragrances flavours division aspart roche group shown discontinuing operations following table continuing operations discontinuing operations group group statement income sales less interdivisional salesa sales third parties expenses operating profit financial income expense net result taxes income taxes result taxes changes accounting policies minority interests share result associated companies net income balance sheet december property plant equipment intangible assets longterm assets current assets total assets longterm debt noncurrent liabilities current liabilities total liabilities net assets statement cash flows operating activities financing activities investing activities net effect currency translation cash increase decrease cash transfer prices interdivisional sales set arms length basis notes consolidated financial statements employee benefitsin millions chf wages salaries social security costs postemployment benefits defined benefit plans postemployment benefits defined contribution plans employee benefits total employees remuneration charges employee benefits included relevant expenditure line function number employees yearend employee benefits consist mainly life insurance schemes certain insurance schemes providing medical dental cover postemployment benefits employees covered retirement benefit plans sponsored group companies nature plans varies according legal regulations fiscal requirements economic con ditions countries employees employed postemployment benefits consist mostly postretirement healthcare life insurance schemes principally united states plans usually funded payments group employees trusts inde pendent ofthe groups finances plan unfunded liability whole obligation recorded groups balance sheet amounts recognised arriving operating profit postemployment defined benefit plans follows current service cost interest cost expected return plan assets net actuarial gains losses recognised past service cost gains losses curtailment total included employees remuneration gains curtailment million swiss francs relate reshaping future growth programme included part pharmaceuticals division restructuring restructuring costs income statement see note actual return plan assets negative return million swiss francs posi tive return million swiss francs notes consolidated financial statements movements net asset liability recognised balance sheet postemployment defined benefit plans follows beginning year changes group organisation givaudan spinoff total expenses included employees remuneration contributions paid benefits paid unfunded plans currency translation effects end year amounts recognised balance sheet postemployment defined benefit plans follows unfunded plans recognised liability actuarial present value unfunded obligations funded plans actuarial present value funded obligations due past present employees plan assets held trusts fair value plan assets excess actuarial present value funded obligations less unrecognised actuarial gains losses unrecognised past service costs net recognised asset liability funded obligations due past present employees asset liability recognised deficit recognised part liabilities postemployment benefits surplus recognised part longterm assets total net asset liability recognised amounts include nonpension postemployment benefit schemes principally medical plans actuarial present value obligations million swiss francs million swiss francs plan assets million swiss francs million swiss francs therelated net liability recognised million swiss francs million swiss francs actuarial gains million swiss francs million swiss francs unrecognised amounts recognised balance sheet postemployment defined benefit plans predom inantly noncurrent reported longterm assets noncurrent liabilities included within fair value assets funded plans groups nonvoting equity securities fair value million swiss francs million swiss francs notes consolidated financial statementsthe group operates defined benefit schemes many countries actuarial assumptions vary based upon local economic social conditions range assumptions used theactuarial valuations significant defined benefit plans countries withstable currencies interest rates follows discount rates projected rates remuneration growth expected rates return plan assets healthcare cost trend rate groups japanese subsidiaries participate tokyo pharmaceutical welfare fund multi employer plan nature defined benefit plan accounted defined contribution plan financial statements group access sufficient information plan account defined benefit plan contributions million swiss francs million swiss francs employees certain us subsidiaries group receive stock appreciation rights sars part compensation sars may exercised vesting period two three years cash payment based upon amount market price groups american depositary shares adss point exercise exceeds strike price grant price issuance group accrues expected cash outflow outstanding sars december accrual required group operates option compensation plan certain employees group purchases options roche nonvoting equity securities financial institutions granted certain employees costs options deferred deduction equity purchased expensed granted employees obligation deliver nonvoting equity securities rests financial institutions operating income expense net millions chf royalty income gain disposal coreg operating income total operating income royalty expense ongoing restructuring expense operating expense total operating expense total operating income expense net notes consolidated financial statements financial income expense net millions chf gains sale marketable securities losses sale marketable securities gains sales labcorp shares dividend income gains losses equity derivatives net writedowns impairments equity investments net income equity investments interest income gains losses interest rate derivatives net writedowns impairments longterm loans total interest income interest expense amortisation discount debt instruments time cost provisions total interest expense foreign exchange gains losses net gains losses foreign currency derivatives net net foreign exchange gains losses financial income expense net total financial income expense net gains losses derivatives shown following implementation new international accounting standard financial instruments recognition measurement january see note income taxes millions chf income tax expenses amounts charged income statement follows current income taxes deferred income taxes total charge income taxes groups parent company roche holding ltd several groups operating companies domiciled switzerland maximum effective rate income taxes companies domiciled basel switzerland holding companies operating companies since group operates across world subject income taxes many different tax jurisdictions group calculates average expected tax rate weighted average tax rates tax jurisdictions group operates rate increased operating income makes considerably higher pro portion pretax income case previous years leads increase groups effective tax rate operating income typically occurs jurisdictions higher tax rates compared financial income notes consolidated financial statementsthe groups effective tax rate differs groups expected tax rate follows groups average expected tax rate tax effect income taxable expenses deductible tax purposes differences gain sale genentech shares gain sale labcorp shares impairment longterm assets vitamin case groups effective tax rate income tax assets liabilities amounts recognised balance sheet income taxes follows current income taxes current income tax assets current income tax liabilities net current income tax asset liability balance sheet deferred income taxes deferred income tax assets deferred income tax liabilities net deferred income tax asset liability balance sheet amounts recognised balance sheet deferred taxes reported longterm assets noncurrent liabilities approximately respectively current deferred income tax assets recognised tax loss carry forwards extent realisation related tax benefit probable group significant unrecognised tax losses deferred income tax liabilities established withholding tax othertaxes would payable unremitted earnings certain foreign subsidiaries assuch amounts currently regarded permanently reinvested unremitted earnings totalled billion swiss francs december billion swiss francs deferred income tax assets liabilities deferred income tax charges credits attributable following items property plant equipment restructuring temporary intangible assets provisions differences total net deferred income tax asset liability beginning year changes accounting policies issue debt instruments charged credited income statement charged credited equity changes group organisation currency translation effects net deferred income tax asset liability end year notes consolidated financial statements property plant equipment restructuring temporary intangible assets provisions differences total net deferred income tax asset liability beginning year changes accounting policies issue debt instruments charged credited income statement changes group organisation including givaudan spinoff currency translation effects net deferred income tax asset liability end year property plant equipment millions chf buildings land machinery improve construction land ments equipment progress total total net book value beginning year currency translation effects changes group organisation including givaudan spinoff genentech synthetic leases additions disposals transfers depreciation charge pharmaceuticals division restructuring impairment charge impairment charges end year december cost accumulated depreciation net book value groups subsidiary genentech synthetic leases certain facilities california innovember genentech entered transaction refinance largest synthetic lease special purpose entity structure groups accounting policy beconsolidated accordingly property plant equipment site net book value million swiss francs recorded groups balance sheet additional million swiss francs recorded shortterm debt addition group considers appro priate record remaining genentech synthetic leases finance leases accordingly hasrecorded additional million swiss francs property plant equipment amount longterm finance lease payable reclassifications recorded effective january groups operating income includes full years depreciation charge facilities effect reclassifica tion reduce net income million swiss francs equivalent amount would million swiss francs notes consolidated financial statementsexcluding genentech synthetic leases december capitalised cost machinery equipment finance leases amounts million swiss francs million swissfrancs net book value assets amounts million swiss francs million swiss francs operating lease commitments december future minimum annual payments noncancellable operating leases follows within one year one five years thereafter total minimum annual payments total rental expense operating leases million swiss francs mil lion swiss francs group capital commitments purchase construction property plant equipment totalling billion swiss francs intangible assets millions chf patents licences trademarks goodwill total total net book value beginning year changes accounting policies currency translation effects changes group organisation including givaudan spinoff additions disposals amortisation charge impairment charge end year december cost accumulated depreciation end year january group recognised impairment charge million swiss francs implementing change accounting policy see note charge million swiss francs credit million swiss francs recognised based changes recoverable amounts impaired assets year notes consolidated financial statements investments associated companies joint venturesin millions chf group investments associated companies listed accounted using equity method share net income balance sheet value laboratory corporation america holdings usa basilea pharmaceutica switzerland investments accounted using equity method total investments accounted using equity method laboratory corporation america holdings june group sold shares labcorp resulting pretax gain incidental costs million swiss francs recorded part financial income expense net net pretax cash inflow million swiss francs date sale groups remaining investment labcorp accounted availableforsale mar ketable securities june labcorp announced called redemption july outstanding convertible preferred stock redemption period group sold suffi cient holding labcorps ordinary stock groups noncontrolling interest labcorp would similar level redemption date group realised pretax gain million swiss francs process october group sold shares labcorp resulting pretax gain incidental costs million swiss francs transactions resulted net pretax cash inflow million swiss francs basilea pharmaceutica october group contributed cash million swiss francs establish newly formed swiss company basilea pharmaceutica ltd basilea group also transferred certain knowhow intellectual property antibiotics antifungals dermatology property plant equipment basilea consideration million swiss francs october group sold shares basilea group retains noncontrolling interest basilea transactions group associated companies follows income statement income sale goods supply services expenses purchase goods supply services balance sheet trade accounts receivable notes consolidated financial statementsbayer joint venture group stake bayer roche llc joint venture bayer group overthecounter otc field market distribute product aleve several otc products united states joint venture included financial statements using theproportionate consolidation method effect income statement balance sheet isas follows income statement sales expenses net income taxes balance sheet longterm assets current assets noncurrent liabilities current liabilities net assets investments millions chf noncurrent investments availableforsale investments heldtomaturity investments total investments investments held strategic purposes therefore classified noncurrent marketable securities held fund management purposes therefore classified current see note following change accounting policy see note availableforsale investments carried fair value availableforsale investments valued lower cost market value fair value availableforsale investments december mil lion swiss francs million swiss francs reported carrying value heldtomaturity investments held amortised cost effective interest rate longterm assets millions chf recognised surplus funded pension plans loans receivable prepaid employee benefits restricted cash total longterm assets loans receivable comprise loans third parties term one year recorded amortised cost restricted cash consists cash set aside collateral certain lease agreements longterm assets consist various assets otherwise shown sepa rately group expects derive economic benefits one year notes consolidated financial statements inventories millions chf raw materials supplies work process finished goods less provision slowmoving obsolete inventory total inventories inventories held net realisable value carrying value million swiss francs million swiss francs accounts receivable trade millions chf accounts receivable notes receivable less provision doubtful accounts total accounts receivable trade december accounts receivable trade include amounts denominated us dollars equivalent billion swiss francs billion swiss francs amounts denominated euros equivalent billion swiss francs billion swiss francs bad debt expense million swiss francs million swiss francs current assetsin millions chf accrued interest income prepaid expenses derivative financial instruments receivables total current assets marketable securitiesin millions chf availableforsale current investments shares bonds debentures money market instruments total marketable securities marketable securities held fund management purposes therefore classified ascurrent investments held strategic purposes classified noncurrent see note following change accounting policy see note marketable securities carried atfair value marketable securities valued lower cost market value fair value marketable securities december million swiss francs million swiss francs reported carrying value shares consist primarily readily saleable equity securities notes consolidated financial statementsbonds debentures contracted maturity amount average effective interest rate within one year one five years five years within one year one five years five years money market instruments generally fixed interest rates ranging depending upon currency denominated contracted mature within one year december accrued current liabilities millions chf deferred income accrued payroll related items interest payable derivative financial instruments accrued liabilities total accrued current liabilities equity share capital annual general meeting april shareholders approved stock split shares nonvoting equity securities roche holding ltd split took place may number shares nonvoting equity securities issue respectively nominal value shares swiss franc nonvoting equity securities nominal value comparative per share information restated split based information supplied roche shareholders group pooled voting rights comprising dr l hoffmann ms v michalskihoffmann ms hoffmann mr hoffmann msv oerihoffmann dr oeri ms duschmaloeri ms c oeri ms b oeri ms oeri dr f gerber group holds shares share split preceding year figure include shares without pooled voting rights held outside group individual members group transactions individuals ordinary course business notes consolidated financial statements nonvoting equity securities genussscheine december nonvoting equity securities issued swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repayment nominal value shares participation certificates accordance law articles incorporation roche holding ltd company isentitled times exchange nonvoting equity securities shares participation certificates dividends april shareholders approved distribution dividend swiss francs per share nonvoting equity security swiss franc respect business year distribution holders outstanding shares nonvoting equity securities totalled million swiss francs recorded retained earnings shareholders also approved special dividend respect givaudan spinoff account ing effect distribution primarily includes carrying value groups financial statements assets liabilities givaudan totalled million swiss francs included special dividend movement retained earnings equity instruments december number nonvoting equity securities held net cash inflow transactions equity instruments million swiss francs net cash outflow million swiss francs group holds equity instruments primarily meet obligations may arise respect certain groups debt instruments may achieved holding physical nonvoting equity securities holding derivative instruments forward contracts call options december group held derivative instruments equivalent nonvoting equity securities instruments exercised total nonvoting equity securities would available group reduction number nonvoting equity securities physically held group increased total number shares outstanding figure used earnings per share calcula tions impact reduce earnings per share earnings per share nonvoting equity security per share information restated share split took place may see note basic earnings per share nonvoting equity security net income millions chf number shares millions number nonvoting equity securities millions weighted average number nonvoting equity securities held millions total millions basic earnings per share nonvoting equity security chf notes consolidated financial statementsdiluted earnings per share nonvoting equity security calculation diluted earnings per share nonvoting equity security weighted average number shares nonvoting equity securities outstanding adjusted assume conversion dilutive potential shares nonvoting equity securities net income millions chf elimination interest expense net tax convertible debt instruments dilutive millions chf increase minority share group net income net tax assuming outstanding genentech stock options exercised net income used calculate diluted earnings per share millions chf weighted average number shares nonvoting equity securities issue millions adjustment assumed conversion convertible debt instruments dilutive millions weighted average number shares nonvoting equity securities issue used calculate dilutive earnings per share millions diluted earnings per share nonvoting equity security chf retained earningsin millions chf fair value fair value reserve reserve accumulated available qualifying equity currency profit forsale cash flow conversion translation loss investments hedges options reserve total total beginning year changes accounting policies net income dividends paid givaudan spinoff special dividend transfer net assets changes fair value recognised net income deferred income taxes minority interests equity component new convertible debt currency translation gains losses total notes consolidated financial statements minority interestsin millions chf beginning year changes accounting policies givaudan spinoff sales genentech shares conversion option embedded lyons iv notes issued minority share group net income net tax net effect movements fair value charged credited equity net effect exercise genentech stock options genentech stock repurchases currency translation effects end year genentech total minority interests genentech december minority interest genentech publicly held third parties groups transactions genentech shares described note december genentech options outstanding employee stock option plans entitled holders exercise options purchase million shares prices ranging usd usd options outstanding million exercisable date debtin millions chf amounts due banks financial institutions debt instruments capitalised lease obligations borrowings total debt less current portion longterm debt amounts due within one year total longterm debt shortterm debt totalling million swiss francs million swiss francs consists current portion longterm debt shown table together shortterm bank loans overdrafts shortterm debt amounting million swiss francs million swiss francs balances include million swiss francs shortterm debt million swiss francs longterm finance lease payable respect genentech synthetic leases see note notes consolidated financial statementsrepayment terms longterm debt within one year one two years two three years three four years four five years thereafter total longterm debt lyons zero coupon us dollar exchangeable notes see reflected due first year holders notes request group purchase notes fair value longterm debt billion swiss francs billion swiss francs iscalculated based upon present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows maturity periods amounts due banks financial institutions interest rates amounts primarily denominated us dollars euros average approximately repayment dates vary years debt instruments carrying value groups debt instruments given table effective interest rate swiss franc bonds bullet due principal billion swiss francs rodeo due principal billion swiss francs us dollar bonds bull spread due principal billion us dollars chameleon due principal billion us dollars japanese yen bonds samurai due principal billion japanese yen swiss franc convertible bonds helveticus dividendlinked convertible bonds due principal billion swiss francs zero coupon us dollar exchangeable notes lyons ii due principal billion us dollars lyons iii due principal billion us dollars lyons iv due principal billion us dollars lyons v due principal billion us dollars japanese yen exchangeable bonds sumo due principal billion japanese yen limited conversion preferred stock total debt instruments notes consolidated financial statements repayment bull spread us dollar bonds due date may group repaid principal amount billion us dollars ofthe us dollar bonds originally issued resulting cash outflow mil lion swiss francs issue lyons v us dollar notes exchangeable nonvoting equity securities july group issued zero coupon us dollar exchangeable notes due july principal amount million us dollars notes exchangeable nonvoting equity securities time prior maturity net proceeds issue million us dollars million swiss francs initially allocated million swiss francs debt million swiss francs unamor tised discount million swiss francs equity respect conversion option embedded bonds million swiss francs deferred tax liability swiss franc convertible bonds helveticus annual payment distribution amount paid july bond chf par value place fixed rate interest annual payment distribution amount equals two hundred times ordinary andor extraordinary dividend declared one nonvoting equity security roche holding ltd business year ended december nineteen months prior july relevant year bond exchangeable one hundred non voting equity securities roche holding ltd time life bond accordance terms bonds additional cash payment chf made upon conversion ofeach bond zero coupon us dollar exchangeable notes lyons ii notes exchangeable american depositary shares adss adjusted exchange ratio exchange adss per usd principal amount maturity notes group purchase note cash option holder april purchase price per usd principal amount notes usd addition notes redeemable option group whole part time april issue price plus accrued original issue discount oid lyons iii notes exchangeable adss exchange ratio exchange adssper usd principal amount maturity notes group purchase note cash option holder may may purchase price per usd principal amount notes usd usd respectively addition notes redeemable option group whole part time may issue price plus accrued original issue discount oid lyons iv notes exchangeable genentech shares exchange ratio genentech shares per usd principal amount maturity notes group right pay cash equal market value genentech shares lieu delivering genen tech shares group purchase note cash option holder january january purchase price per usd principal amount notes usd usd respectively addition notes redeemable option group whole part time january issue price plus accrued original issue discount oid notes consolidated financial statementslyons v notes exchangeable adss exchange ratio exchange adssper usd principal amount maturity notes group purchase note cash option holder january july july purchase price per usd principal amount notes usd usd usd respectively addition notes redeemable option group inwhole part time july issue price plus accrued original issue discount oid japanese yen exchangeable bonds sumo bond jpy par value exchangeable one hundred nonvoting equity securities roche holding ltd exchange ratio bonds redeemable maturity issue price plus accrued original issue discount oid unamortised discount included within carrying value debt instruments following unamortised discounts swiss franc bonds us dollar bonds japanese yen bonds swiss franc convertible bonds zero coupon us dollar exchangeable notes japanese yen exchangeable bonds total unamortised discount derivative financial instruments millions chf appropriate circumstances group uses derivative financial instruments part risk management trading strategies discussed note following change accounting policy derivative financial instruments carried fair value change accounting policy methods used determining fair value described note fair value derivative financial instruments december million swiss francs million swiss francs reported carrying value foreign currency derivatives forward exchange contracts swaps options interest rate derivatives swaps derivatives total carrying value derivative financial instruments asset liability recognised current assets accrued current liabilities total net asset liability recognised notes consolidated financial statements hedge accounting following implementation new international accounting standard financial instruments recognition measurement group changed policy hedge account ing effective january new policy described note requires toqualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence hedge effectiveness reliability measurement described note group financial risk management policies cover foreign exchange risk interest rate risk market risk credit risk liquidity risk deemed appropri ate certain risks altered use derivatives many transactions considered hedges economic terms required conditions met relationship qualify hedge accounting case hedging instru ment hedged item reported independently hedging relationship means derivatives reported fair value changes fair value included financial income expense due considerable administrative cost maintaining necessary documentation tracking procedures group generally limits use hedge accounting certain signifi cant transactions consequently december group fair value hedges cash flow hedges hedges net investment foreign entity meet strict requirements qualify hedge accounting apart described fair value hedges group equity investments various biotechnology companies subject greater risk market fluctuation stock market general manage part exposure group enters derivative financial instruments zero cost collars forward contracts changes fair values reported financial income expense cash flow hedges group expected foreign currency cash flows future royalty income development expenses hedge part transaction exposure group enters derivative financial instruments options forward contracts group also anticipated cash flows interestbearing investments exposed changes interest rates manage part risk group enters interest rate swap agreements effectively convert part expected interest income variable fixed rate move ments fair value reserve designated cash flow hedges disclosed note notes consolidated financial statements provisions millions chf restructuring provisions provisions total total beginning year changes group organisation including givaudan spinoff pharmaceuticals division restructuring additional provisions created amounts utilised year additional provision created respect vitamin case provisions additional provisions created unused amounts reversed utilised year increase discounted amount due passage time change discounting rate currency translation effects end year current portion provisions noncurrent portions provisions total provisions restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provi sions include costs necessarily entailed restructuring associated ongoing activities group creation provisions recorded charge operating income except arise restructuring newly acquiredcompanies case included acquisition accounting hence form part goodwill see also note regarding pharmaceuticals division restructuring provisions consist mainly legal environmental similar matters provisions include provisions respect vitamin case see note contingent liabilities operations earnings group continue time time varying degrees affected political legislative fiscal regulatory developments including relating environmental protection countries operates industries group engaged also subject physical risks various kinds nature frequency developments events covered insurance well effect future operations earnings predictable notes consolidated financial statements vitamin case provisions recorded respect vitamin case disclosed note provi sions groups best current estimate total liability may arise assessment based currently available information litigation process new litigation may arise possible final obligation may different igen litigation february united states district court maryland entered judgement civil litigation roche diagnostics gmbh germany rdg igen international inc igen claims related licensing igens electrochemiluminescence ecl rdg court concluded several breaches licence agreement material igen right terminate licence agreement awarded igen million us dollars compensatory damages million us dollars punitive damages rdg file appeal decision existing order court bars licence termination appeal proceedings completed appeal progress rdg continue provide customers products services continue planned innovations based ecl technology rdg previously boehringer mannheim litigation since matters acquiring boehringer mannheim rdg assessed igen litigation adequacy provision already recorded boehringer mannheim rdg reassessed adequacy provisions concluded based currently available information appropriate record additional provisions point total amount provisions liability thatrdg expects pay adjusted foreign currency translation effects time value money litigation process possible final obligation may different total amount provisions disclosed may prejudice rdg position current litigation however provisions significantly less amounts awarded court cash flow statementin millions chf cash flows operating activities cash flows operating activities derived groups primary activities asdescribed divisional review calculated indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation impairment order derive cash generated operations operating cash flows shown cash flow statement operating cash flows also include income taxes paid activities including example taxes paid gains genentech labcorp share sales notes consolidated financial statements net income add back nonoperating income expense financial income expense net income taxes changes accounting policies income applicable minority interests share result associated companies operating profit depreciation property plant equipment amortisation intangible assets impairment longterm assets gain sale genentech shares charge vitamin case charge pharmaceuticals division restructuring genentech inventory writeup charged expense defined benefit postemployment plans adjustments cash generated operations cash flows financing activities cash flows financing activities primarily proceeds issue repayments groups equity debt instruments also include interest payments dividend payments instruments cash flows shortterm financing including finance leases also included cash flows indicate groups transactions providers equity debt financing cash flows shortterm borrowings shown net movement consist large number transactions short maturity proceeds issue longterm debt lyons v zero coupon exchangeable us dollar notes due lyons iv zero coupon exchangeable us dollar notes due sumo exchangeable japanese yen bonds due longterm bank loans borrowings total repayment longterm debt repayment bull spread us dollar bonds repayment knock us dollar bonds exercise helveticus dividendlinked swiss francs convertible bonds longterm bank loans borrowings total interest dividends paid interest paid dividends paid total notes consolidated financial statements cash flows investing activities cash flows investing activities principally arising groups investments inproperty plant equipment intangible assets acquisition divestment subsidiaries associated companies businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets cash flow effects changes group organisation well cash generated groups investments cash flows marketable securities including income capital gains losses shown net movement groups portfolio consist large number positions held longterm basis acquisitions subsidiaries associated companies products amira cash contribution basilea acquisitions total divestments subsidiaries associated companies products proceeds sale genentech shares proceeds sales labcorp shares divestments total interest dividends received interest received dividends received total subsequent events vitamins fine chemicals division management begun evaluation strategic options respect vitamins andfine chemicals division date approval financial statements board directors approved detailed formal plan announcement intentions madeaccordingly vitamins fine chemicals division remains classified part continuingoperations financial statements sale labcorp shares february labcorp filed registration statement announcing group plans offer sale million shares labcorp option sell million shares cover overallotments assuming total million shares would sold roches ownership interest labcorp would reduced approximately approxi mately notes consolidated financial statementsreport group auditors general meeting roche holding ltd basel auditors group audited consolidated financial statements roche group pages year ended december consolidated financial statements responsibility board directors roche holding ltd responsibility express opinion consolidated financial statements based audit confirm meet swiss legal requirements con cerning professional qualification independence audit conducted accordance auditing standards promulgated swiss pro fession international standards auditing issued international federation accountants require audit planned performed obtain reasonable assurance whether consolidated financial statements free material misstate ment examined test basis evidence supporting amounts disclosures theconsolidated financial statements also assessed accounting principles used significant estimates made overall consolidated financial statement presentation webelieve audit provides reasonable basis opinion opinion consolidated financial statements roche group present fairly material respects financial position december results operations cash flows year ended accordance international accounting standards comply swiss law recommend consolidated financial statements submitted approved pricewaterhousecoopers ag william kirst richard tgwinter basel february report group auditors multiyear overview statistics reported statement income millions chf sales ebitda operating profit net income research development balance sheet millions chf longterm assets current assets total assets equity minority interests noncurrent liabilities current liabilities additions property plant equipment personnel number employees end year key ratios net income sales net income equity research development sales current ratio equity minority interests total assets sales per employee thousands chf data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf cash warrants addition dividend adjusted chf cash warrants addition dividend unadjusted chf information table stated reported changes accounting policy arising changes international accounting standards stock split arenot applied retrospectively warrants held final exercise date b addition normal dividend shareholders approved share nonvoting equity security special ro centenary warrant worth chf date issue holders option cash equivalent chf c net income related key ratios shown special charges million swiss francs net tax incurred following corange acquisition include corange respect balance sheet data multiyear overview c e f b e f warrants held final exercise date e dividend include special dividend relating spinoff fragrances flavours division f dividend proposed board directors multiyear overview sales division millions chf pharmaceuticals diagnostics vitamins fine chemicals fragrances flavours total sales geographical area millions chf switzerland european union rest europe europe north america latin america asia africa australia oceania total additions property plant equipment division millions chf pharmaceuticals diagnostics vitamins fine chemicals fragrances flavours others total additions property plant equipment geographical area millions chf switzerland european union rest europe europe north america latin america asia africa australia oceania total multiyear overviewholding finance companies boehringer mannheim far east pte ltd singapore corange deutschland holding gmbh mannheim germany corange ltd hamilton bermuda hoffmannla roche france sas neuillysurseine france roche capital corporation panama city panama roche capital market international limited st peter port guernsey roche capital transactions limited hamilton bermuda roche china limited shanghai china roche deutschland holding gmbh grenzachwyhlen germany roche financial management inc panama city panama roche financial products limited hamilton bermuda roche finanz ag basel switzerland roche holding uk limited welwyn garden city great britain roche holdings inc wilmington delaware usa roche international finance bermuda ltd hamilton bermuda roche international finance corporation limited st peter port guernsey roche international ltd hamilton bermuda roche kapitalmarkt ag basel switzerland roche pharmholding bv mijdrecht netherlands roche treasury management europe ltd basel switzerland roche vitamins holding ag basel switzerland sapac corporation ltd montevideo uruguay syntex corporation panama city panama companies wholly owned group holding finance companies roche securities share price performance chf roche share adjusted swiss market index rebased nonvoting equity security genussschein price performance chf roche nonvoting equity security adjusted swiss market index rebased american depositary receipt adr price performance usd roche adr adjusted sp index rebased one roche american depositary receipt adr equivalent one nonvoting equity security genussschein adrs traded united states overthecounter market since july roche securitiesnumber shares nonvoting equity securitiesa number shares nominal value chf chf number nonvoting equity securities genussscheineno nominal value total data per share nonvoting equity securityc chf net income equity dividend e f stock price shareb high low yearend stock price nonvoting high equity security low genussscheinb yearend historic stock price unadjusted share yearend nonvoting equity security genussschein yearend market capitalisation unadjusted millions chf yearend key ratios yearend net income equity dividend yield shares dividend yield nonvoting equity securities genussscheinein priceearnings shares unadjusted priceearnings nonvoting equity securities genussscheine unadjusted nonvoting equity security genussschein confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices stock price figures prior june adjusted effects givaudan spinoff adjustment factors used shares nonvoting equity securities factors used independent financial institutions c net income per share prior market capitalisation figures assume equity instruments held outstanding net income related key ratios shown special charges million swiss francs net tax incurred following corange acquisition include corange respect balance sheet data e dividend include special dividend relating spinoff fragrances flavours division f dividend proposed board directors ticker symbols share nonvoting american equity security depositary receipt reuters roczs roczgs rohhypk bloomberg ro sw rog sw rohhy us swx swiss exchange ro rog roche securities outstanding bonds summarised bond terms exchange terms warrants samurai may warrants exercised june holder face value jpy billion warrants received chf cash coupon issuer roche financial management inc keep well roche holding ltd attached warrants relating roche nonvoting equity securities genussscheine lyons april notes exchangeable american depositary shares face value usd adss adjusted exchange ratio exchange coupon zero adss per usd principal amount maturity notes issuer roche holdings inc exchange ratio changed accordance inden keep well roche holding ltd ture agreement dated april effective date exchange right roche adss may group purchase note cash option holder april purchase price perusd principal amount notes usd inaddition notes redeemable option group whole part time april issue price plus accrued original issue discount oid helveticus july bond chf par value exchangeable one non face value chf voting equity security roche holding ltd time coupon times ordinary andor life bond accordance terms bonds extraordinary dividend nonvoting additional cash payment chf made upon conver equity securities genussscheine sion bond chf par value issuer roche capital market international limited keep well roche holding ltd conversion right roche nonvoting equity securities lyons may notes exchangeable american depositary shares face value usd adss exchange ratio exchange adss per coupon zero usd principal amount maturity notes issuer roche holdings inc exchange ratio changed accordance indenture keep well roche holding ltd agreement dated may effective date may exchange right roche adss group purchase note cash optionof holder may may pur chase price per usd principal amount notes usd usd respectively addition notes willbe redeemable option group whole part atany time may issue price plus accrued original issue discount oid roche securitiesoutstanding bonds summarised bond terms exchange terms warrants rodeo march warrants expired unexercised march face value chf coupon issuer roche kapitalmarkt ag keep well roche holding ltd attached warrants roche nonvoting equity securities genussscheine bullet march face value chf coupon issuer roche international finance corporation limited keep well roche holding ltd chameleon july face value usd coupon issuer roche holdings inc keep well roche holding ltd lyons january notes exchangeable genentech shares face value usd exchange ratio genentech shares per usd coupon zero principal amount maturity notes group issuer roche holdings inc theright pay cash equal market value genen keep well roche holding ltd tech shares lieu delivering genentech shares group exchange right purchase note cash option holder genentech common stock january january purchase price per usd principal amount notes usd andusd respectively addition notes redeemable option group whole part anytime january issue price plus accrued original issue discount oid sumo march bond jpy par value exchangeable one face value jpy hundred nonvoting equity securities roche holding ltd coupon exchange ratio bonds redeemable issuer roche holdings inc maturity attheissue price plus accrued original issue keep well roche holding ltd discount oid exchange right roche nonvoting equity securities genussscheine accordance terms bonds exchange ratio adjusted june may roche securities outstanding bonds summarised bond terms exchange terms warrants lyons july notes exchangeable american depositary shares face value usd adss exchange ratio exchange adss per coupon zero usd principal amount maturity notes group issuer roche holdings inc purchase note cash option holder keep well roche holding ltd january july july purchase exchange right roche adss price per usd principal amount notes usd usd usd respectively addition notes redeemable option group whole part time july issue price plus accrued original issue discount oid roche securitiesroche holding ltd basel financial statements income statement millions chf income income participations interest income loans group companies interest investment income income total income expense financial expense administration expense expense total expense profit year taxes taxes net profit year financial statements balance sheet december millions chf longterm assets participations loans group companies total longterm assets current assets accounts receivable group companies accounts receivable prepaid expenses accrued income marketable securities liquid funds total current assets total assets equity share capital nonvoting equity securities genussscheine pm pm general legal reserve free reserve special reserve available earnings balance brought forward previous year net profit year total equity noncurrent liabilities provisions total noncurrent liabilities current liabilities accounts payable group companies liabilities accrued liabilities total current liabilities total liabilities total equity liabilities pm pro memoria nonvoting equity securities nominal value financial statementsnotes financial statements general financial statements roche holding ltd basel prepared accordance provisions swiss company law accepted business principles valuation methods translation foreign currencies balance sheet assets liabilities disclosed net realisable values exceptions tothis rule participations shown acquisition values less appropriate writedowns marketable securities shown lower cost market value unrealised foreign currency gains balance sheet items deferred expenses income aswell foreign currency transactions translated exchange rates ruling relevant transaction dates details specific items income total income million swiss francs million swiss francs higher previous year mainly due improved operating income taxes tax charge includes corporate income capital taxes withholding taxes stamp duty equity total equity equals total assets share capital previous year share capital amounts million swiss francs annual general meeting decided april split bearer shares non voting equity securitiesfrom split took place may share capital consists bearer shares nominal value chf nonvoting equity securitiesgenussscheine nominal value guarantees guarantees favour group companies total million swiss francs previous year million swiss francs time preparing balance sheet risks arising contingent liabilities discernible pledged assets assets total book value million swiss francs previous year pledged security companys commitments notes financial statements participations major participations listed pages important shareholders shares company issued bearer reason company notkeep register shareholders following figures based information share holders shareholder validation check annual general meeting april onother information available company previous year stock split shares shareholders groupwith pooled voting rights comprising dr l hoffmann ms v michalskihoffmann msmahoffmann mr hoffmann msv oerihoffmann dr oeri ms duschmaloeri ms c oeri ms b oeri ms oeri anddr f gerbera shares novartis ag basel including affiliates thereofb information supplied shareholders december figure shares include shares without pooled voting rights held outside group individual members group b figures december supplied novartis international ltd basel notes financial statementsappropriation available earnings proposals general meeting chf available earnings net profit year balance brought forward previous year total available earnings appropriation available earnings distribution ordinary dividend chf gross per share nonvoting equity security genussschein chf stock split last year transfer free reserve total appropriation available earnings carried forward account appropriation available earnings report statutory auditors general meeting roche holding ltd basel statutory auditors audited accounting records financial statements income statement balance sheet notes pages roche holding ltd basel forthe year ended december financial statements responsibility board directors responsibility toexpress opinion financial statements based audit confirm meet legal requirements concerning professional qualification independence audit conducted accordance auditing standards promulgated swiss profession require audit planned performed manner obtain reasonable assurance whether financial statements free material misstatement examined test basis evidence supporting amounts disclosures financial statements also assessed accounting principles used significant estimates made overall financial statement presentation believe audit provides reasonable basis opinion opinion accounting records financial statements proposed appropriation available earnings comply swiss law companys articles incorporation recommend financial statements submitted approved ernst young ltd conrad lffel jrg zrcher basel february report statutory auditors arctic circle tropic cancer tropic capricorn roche ct ia rcrc letic global market presence sales switzerland manufacturing argentina research development australia toe lr lv mic ae ns u f fi ca tn uc rii nn gg third parties austria bangladesh belgium bermuda brazil canada chile china colombia costa rica czech republic denmark dominican republic ecuador egypt el salvador finland france germany great britain greece guatemala roche global market presence arctic circle tropic cancer tropic capricorn cnt ia rcrc letic honduras south korea hungary spain india sweden indonesia taiwan ireland thailand israel turkey italy uruguay japan usa malaysia venezuela mexico vietnam morocco netherlands new zealand nicaragua norway pakistan panama peru philippines poland portugal puerto rico russia singapore south africa roche global market presence operating subsidiaries associated companies group holds interest switzerlandf hoffmannla roche ltd roche diagnostics hong kong limited mostofthe companies listed exceptions basel roche ltd sisseln teranol ltd hong kong colombia productos roche aremarked either single dot lalden roche pharma switzerland sa bogot roche vitaminas colom group interest ltd reinach roche diagnostics bia sa bogot costa rica productos double dot group interest schweiz ltd rotkreuz roche diag roche interamericana sa san jos nostics international ltd cham roche roche servicios sa san jos roche vitamins europe ltd birsfelden roche costa rica sa san jos roche vita december instrument center ltd rotkreuz roche minas costa rica sa san jos czech consumer health ltd kaiseraugst republic roche sro prague denmark includes changes group membership roche vitamins ltd basel basilea roche hvidovre roche vitamins february pharmaceutica ltd basel argentina hvidovre dominican republic pro productos roche sa qumica e indus ductos rochedominicana sa santo trial buenos aires roche vitaminas domingo roche vitaminas domini argentina sa buenos aires australia cana sa santo domingo ecuador roche products pty limited dee roche ecuador sa quito egypt roche vitamins australia pty limited rovigypt ltd giza roche egypt ltd french forest syntex australia limited giza el salvador productosroche north sydney roche diagnostics aus elsalvador sa san salvador tralia pty limited castle hill austria finlandroche oy espoo france roche austria gmbh vienna roche hoffmannlaroche france sas diagnostics gmbh vienna bangladesh neuillysurseine produits roche sa roche bangladesh ltd dhaka neuillysurseine roche diagnostics belgiumnv roche sa brussels sa meylan roche vitamines france sacitrique belge nv tienen roche sa villageneuf laboratoires roche vitamins nv deinzeastene roche nicholas sa gaillard germany roche diagnostics belgium sa brussels deutschland holding gmbh grenzach bermuda syntex pharmaceuticals wyhlen corange deutschland holding international limited hamilton brazil gmbh mannheim consulab mannheim produtos roche qumicos e farmacuti gmbh mannheim pharma waldhof cos sa paulo avl ltda gmbh co kg mannheim hoffmann paulo roche vitaminas brasil ltda la roche aktiengesellschaft grenzach paulo canadahoffmannla roche wyhlen roche consumer health limited toronto roche vitamins deutschland gmbh eppstein roche canada inc cambridge ontario chile diagnostics gmbh mannheim galenus productos roche ltda santiago de mannheim gmbh mannheim hestia chile roche vitaminas chile sa pharma gmbh mannheim roche vita puerto montt china roche shanghai mine gmbh grenzachwyhlen great fine chemicals ltd shanghai roche britain roche products limited welwyn china limited shanghai shanghai garden city roche diagnostics ltd roche pharmaceuticals limited shang lewes roche vitamins uk ltd hai roche shanghai vitamins ltd welwyn garden city roche registration shanghai roche zhongya wuxi limited welwyn garden city greece citric acid ltd wuxi roche diagnos roche hellas sa athens roche tics shanghai limited shanghai vitamins hellas epe athens roche roche hong kong limited hong kong vitamins international marketing centre operating subsidiaries associated companiesepe athens guatemala productos productos roche panam sa panama uruguay sa montevideo usa roche roche guatemala sa guatemala city roche vitaminas interamrica holdings inc wilmington delaware honduras productos roche honduras sa panama city peru productos hoffmannlaroche inc nutley new sa tegucigalpa hungary roche roche qumica farmacutica sa lima jersey roche laboratories inc nutley hungary ltd budapest roche vitamins philippines roche philippines inc new jersey roche vitamins inc hungary ltd ujhartyan india roche makati roche vitamins philippines parsippany new jersey roche scientific company india private inc manila poland roche polska molecular systems inc pleasanton limited mumbai indonesia pt roche spzoo warsaw roche diagnostics california american roche interna indonesia jakarta ireland roche polska sp z oo warsaw roche tional inc little falls new jersey products ireland limited dublin witaminy polska sp zoo mszczonw roche carolina inc florence south roche ireland limited clarecastle portugal roche farmacutica qumica carolina genentech inc south san israel roche pharmaceuticals israel lda amadora roche sistemas de francisco california syntex usa ltd telaviv italy roche spa milan diagnsticos sociedade unipessoal llc palo alto california roche roche diagnostics spa milan istituto lda lindaavelha puerto rico syntex colorado corporation boulder delle vitamine spa milan japan puerto rico inc humacao russia colorado bayerroche llc nippon roche kk tokyo nutritec roche moscow ltd moscow singa morristown new jersey roche co ltd tokyo roche diagnostics pore roche singapore pte ltd singa diagnostics corporation indianapolis kk tokyo roche vitamins japan kk pore roche diagnostics asia pacific indiana venezuela productos roche tokyo malaysia roche malaysia sdn pte ltd singapore roche vitamins sa caracas roche vitaminas bhd kuala lumpur roche diagnostics asia pacific pte ltd singapore south venezuela sa la victoriavietnam malaysia sdn bhd kuala lumpur africa roche products proprietary roche vitamins vietnam limited roche vitamins malaysia sdn bhd limited johannesburg south korea binhduong province kuala lumpur mexico productos roche korea company ltd seoul roche sa de cv mexico city syntex roche diagnostics korea co ltd sa de cv mexico city grupo roche seoul roche vitamins korea ltd syntex de mxico sa de cv mexico seoul spain roche farma sa madrid city lakeside de mxico sa de cv march roche vitaminas mexico city roche vitaminas mxico sa madrid andreu roche sa sa de cv el salto jalisco morocco madrid syntex roche sa madrid roche sa casablanca roche immo roche diagnostics sl barcelona bilire maroc sarl casablanca boehringer mannheim roche sa thenetherlands roche pharmholding madrid sweden roche ab stockholm bv mijdrecht roche nederland bv roche diagnostics scandinavia ab mijdrecht roche diagnostics neder bromma taiwan roche products ltd land bv almere roche vitamins bv taipei roche diagnostics ltd taipei venlo new zealand roche products roche vitamins taiwan limited taipei new zealand limited auckland thailand roche thailand limited roche vitamins new zealand limited bangkok rovithai limited bangkok auckland roche diagnostics new roche diagnostics thailand limited zealand pty ltd auckland nicaragua bangkok turkey roche mstahzarlar productos roche nicaragua sa sanayi anonim sirketi istanbul roche managua norway roche norge diagnostik sistemleri ticaret oslo pakistan roche pakistan ltd istanbul uruguay roche international karachi panama productos roche ltd montevideo sapac corporation interamericana sa panama city ltd montevideo roche vitaminas operating subsidiaries associated companies cautionary statement regarding forwardlooking statements annual report contains certain forward opments economic conditions delay looking statements forwardlooking inability obtaining regulatory approvals bring statements may identified bywords ing products market fluctuations currency believes expects anticipates projects intends exchange rates general financial market seeks estimates future similar conditions uncertainties discovery devel expressions discussion among opment marketing new products new uses things strategy goals plans intentions various existing products increased government factors may cause actual results differ materially pricing pressures interruptions production future reflected forwardlook loss inability obtain adequate protection ing statements contained annual report intellectual property rights litigation among others pricing product initiatives loss key executives orother employees ofcompetitors legislative regulatory devel adverse publicity news coverage published f hoffmannla roche ltd basel switzerland tel fax media office corporate communications basel switzerland tel fax investor relations basel switzerland tel fax world wide web httpwwwrochecom order tel fax publications email baselwebmasterrochecom next annual general meeting april trademarks mentioned enjoy legal protection roche annual report published german original language english roche annual report issued f hoffmannla roche ltd basel corporate communications design wirz identity ag zurich photos tina steinauer zurich roche corporate photolibrary basel typesetting staufferfebel ag basel lithos lithoteam ag allschwilbasel printers birkhusergbc ag reinachbasel binding buchbinderei grollimund ag reinachbasel cover influenza virus transmission electron microscopyvitamins fine chemicals diagnostics sales division pharmaceuticals latin america others asia sales region europe north america vitamins fine chemicals others diagnostics employees division pharmaceuticals latin america others asia employees region north america europe